3zyu › Citations

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T
Nature 478 529-33 (2011)
Cited: 925 times
EuropePMC logo PMID: 21964340

Abstract

Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene initiate aggressive forms of leukaemia, which are often refractory to conventional therapies. Many MLL-fusion partners are members of the super elongation complex (SEC), a critical regulator of transcriptional elongation, suggesting that aberrant control of this process has an important role in leukaemia induction. Here we use a global proteomic strategy to demonstrate that MLL fusions, as part of SEC and the polymerase-associated factor complex (PAFc), are associated with the BET family of acetyl-lysine recognizing, chromatin 'adaptor' proteins. These data provided the basis for therapeutic intervention in MLL-fusion leukaemia, via the displacement of the BET family of proteins from chromatin. We show that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis. I-BET151 treatment in two human leukaemia cell lines with different MLL fusions alters the expression of a common set of genes whose function may account for these phenotypic changes. The mode of action of I-BET151 is, at least in part, due to the inhibition of transcription at key genes (BCL2, C-MYC and CDK6) through the displacement of BRD3/4, PAFc and SEC components from chromatin. In vivo studies indicate that I-BET151 has significant therapeutic value, providing survival benefit in two distinct mouse models of murine MLL-AF9 and human MLL-AF4 leukaemia. Finally, the efficacy of I-BET151 against human leukaemia stem cells is demonstrated, providing further evidence of its potent therapeutic potential. These findings establish the displacement of BET proteins from chromatin as a promising epigenetic therapy for these aggressive leukaemias.

Reviews - 3zyu mentioned but not cited (3)

  1. Readout of epigenetic modifications. Patel DJ, Wang Z. Annu Rev Biochem 82 81-118 (2013)
  2. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Feng L, Wang G, Chen Y, Chen Y, He G, Liu B, Liu J, Chiang CM, Ouyang L. Med Res Rev 42 710-743 (2022)
  3. Targeting bromodomain-containing proteins: research advances of drug discovery. Pan Z, Zhao Y, Wang X, Xie X, Liu M, Zhang K, Wang L, Bai D, Foster LJ, Shu R, He G. Mol Biomed 4 13 (2023)

Articles - 3zyu mentioned but not cited (17)

  1. Design and characterization of bivalent BET inhibitors. Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE. Nat Chem Biol 12 1089-1096 (2016)
  2. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. Hewings DS, Fedorov O, Filippakopoulos P, Martin S, Picaud S, Tumber A, Wells C, Olcina MM, Freeman K, Gill A, Ritchie AJ, Sheppard DW, Russell AJ, Hammond EM, Knapp S, Brennan PE, Conway SJ. J Med Chem 56 3217-3227 (2013)
  3. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. Ran X, Zhao Y, Liu L, Bai L, Yang CY, Zhou B, Meagher JL, Chinnaswamy K, Stuckey JA, Wang S. J Med Chem 58 4927-4939 (2015)
  4. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth. Ren C, Zhang G, Han F, Fu S, Cao Y, Zhang F, Zhang Q, Meslamani J, Xu Y, Ji D, Cao L, Zhou Q, Cheung KL, Sharma R, Babault N, Yi Z, Zhang W, Walsh MJ, Zeng L, Zhou MM. Proc Natl Acad Sci U S A 115 7949-7954 (2018)
  5. Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome. Schulz D, Mugnier MR, Paulsen EM, Kim HS, Chung CW, Tough DF, Rioja I, Prinjha RK, Papavasiliou FN, Debler EW. PLoS Biol 13 e1002316 (2015)
  6. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. Allen BK, Mehta S, Ember SW, Schonbrunn E, Ayad N, Schürer SC. Sci Rep 5 16924 (2015)
  7. HADDOCK(2P2I): a biophysical model for predicting the binding affinity of protein-protein interaction inhibitors. Kastritis PL, Rodrigues JP, Bonvin AM. J Chem Inf Model 54 826-836 (2014)
  8. Waterdock 2.0: Water placement prediction for Holo-structures with a pymol plugin. Sridhar A, Ross GA, Biggin PC. PLoS One 12 e0172743 (2017)
  9. SAR by Space: Enriching Hit Sets from the Chemical Space. Klingler FM, Gastreich M, Grygorenko OO, Savych O, Borysko P, Griniukova A, Gubina KE, Lemmen C, Moroz YS. Molecules 24 E3096 (2019)
  10. Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations. Allen BK, Mehta S, Ember SWJ, Zhu JY, Schönbrunn E, Ayad NG, Schürer SC. ACS Omega 2 4760-4771 (2017)
  11. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4. Rodríguez Y, Gerona-Navarro G, Osman R, Zhou MM. Proteins 88 414-430 (2020)
  12. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. Bharatham N, Slavish PJ, Shadrick WR, Young BM, Young BM, Shelat AA. J Mol Graph Model 81 197-210 (2018)
  13. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches. Tahir A, Alharthy RD, Naseem S, Mahmood N, Ahmed M, Shahzad K, Akhtar MN, Hameed A, Sadiq I, Nawaz H, Muddassar M. Molecules 23 E1527 (2018)
  14. Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Li Y, Zhao J, Gutgesell LM, Shen Z, Ratia K, Dye K, Dubrovskyi O, Zhao H, Huang F, Tonetti DA, Thatcher GRJ, Xiong R. J Med Chem 63 7186-7210 (2020)
  15. Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay. Chen Z, Zhang H, Liu S, Xie Y, Jiang H, Lu W, Xu H, Yue L, Zhang Y, Ding H, Zheng M, Yu K, Chen K, Jiang H, Luo C. Medchemcomm 8 1322-1331 (2017)
  16. WONKA and OOMMPPAA: analysis of protein-ligand interaction data to direct structure-based drug design. Deane CM, Wall ID, Green DV, Marsden BD, Bradley AR. Acta Crystallogr D Struct Biol 73 279-285 (2017)
  17. A Functional Bayesian Model for Hydrogen-Deuterium Exchange Mass Spectrometry. Crook OM, Gittens N, Chung CW, Deane CM. J Proteome Res 22 2959-2972 (2023)


Reviews citing this publication (318)

  1. Cancer epigenetics: from mechanism to therapy. Dawson MA, Kouzarides T. Cell 150 12-27 (2012)
  2. The molecular hallmarks of epigenetic control. Allis CD, Jenuwein T. Nat Rev Genet 17 487-500 (2016)
  3. PI3K and cancer: lessons, challenges and opportunities. Fruman DA, Rommel C. Nat Rev Drug Discov 13 140-156 (2014)
  4. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Falkenberg KJ, Johnstone RW. Nat Rev Drug Discov 13 673-691 (2014)
  5. Epigenetic protein families: a new frontier for drug discovery. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Nat Rev Drug Discov 11 384-400 (2012)
  6. Targeting bromodomains: epigenetic readers of lysine acetylation. Filippakopoulos P, Knapp S. Nat Rev Drug Discov 13 337-356 (2014)
  7. Protein arginine methyltransferases and cancer. Yang Y, Bedford MT. Nat Rev Cancer 13 37-50 (2013)
  8. Transcriptional Addiction in Cancer. Bradner JE, Hnisz D, Young RA. Cell 168 629-643 (2017)
  9. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Shi J, Vakoc CR. Mol Cell 54 728-736 (2014)
  10. Epigenetic Determinants of Cancer. Baylin SB, Jones PA. Cold Spring Harb Perspect Biol 8 a019505 (2016)
  11. Getting up to speed with transcription elongation by RNA polymerase II. Jonkers I, Lis JT. Nat Rev Mol Cell Biol 16 167-177 (2015)
  12. DNA methylation profiling in the clinic: applications and challenges. Heyn H, Esteller M. Nat Rev Genet 13 679-692 (2012)
  13. Cancer stem cell definitions and terminology: the devil is in the details. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Nat Rev Cancer 12 767-775 (2012)
  14. BET domain co-regulators in obesity, inflammation and cancer. Belkina AC, Denis GV. Nat Rev Cancer 12 465-477 (2012)
  15. Histone Modifications and Cancer. Audia JE, Campbell RM. Cold Spring Harb Perspect Biol 8 a019521 (2016)
  16. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Bantscheff M, Lemeer S, Savitski MM, Kuster B. Anal Bioanal Chem 404 939-965 (2012)
  17. Targeting oncogenic Myc as a strategy for cancer treatment. Chen H, Liu H, Qing G. Signal Transduct Target Ther 3 5 (2018)
  18. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Rao RC, Dou Y. Nat Rev Cancer 15 334-346 (2015)
  19. Chromatin proteins and modifications as drug targets. Helin K, Dhanak D. Nature 502 480-488 (2013)
  20. Targeting epigenetic readers in cancer. Dawson MA, Kouzarides T, Huntly BJ. N Engl J Med 367 647-657 (2012)
  21. Protein lysine acetylation by p300/CBP. Dancy BM, Cole PA. Chem Rev 115 2419-2452 (2015)
  22. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Marmorstein R, Zhou MM. Cold Spring Harb Perspect Biol 6 a018762 (2014)
  23. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Nat Rev Genet 14 765-780 (2013)
  24. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Fujisawa T, Filippakopoulos P. Nat Rev Mol Cell Biol 18 246-262 (2017)
  25. BRD4 and Cancer: going beyond transcriptional regulation. Donati B, Lorenzini E, Ciarrocchi A. Mol Cancer 17 164 (2018)
  26. The super elongation complex (SEC) family in transcriptional control. Luo Z, Lin C, Shilatifard A. Nat Rev Mol Cell Biol 13 543-547 (2012)
  27. An overview of MYC and its interactome. Conacci-Sorrell M, McFerrin L, Eisenman RN. Cold Spring Harb Perspect Med 4 a014357 (2014)
  28. Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation. Core L, Adelman K. Genes Dev 33 960-982 (2019)
  29. The bromodomain interaction module. Filippakopoulos P, Knapp S. FEBS Lett 586 2692-2704 (2012)
  30. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Grimwade D, Ivey A, Huntly BJ. Blood 127 29-41 (2016)
  31. Epigenetics in cancer stem cells. Toh TB, Lim JJ, Chow EK. Mol Cancer 16 29 (2017)
  32. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Winters AC, Bernt KM. Front Pediatr 5 4 (2017)
  33. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Dawson MA. Science 355 1147-1152 (2017)
  34. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Abdel-Wahab O, Levine RL. Blood 121 3563-3572 (2013)
  35. Targeting protein-protein interactions as an anticancer strategy. Ivanov AA, Khuri FR, Fu H. Trends Pharmacol Sci 34 393-400 (2013)
  36. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Oh S, Shin S, Janknecht R. Biochim Biophys Acta 1826 1-12 (2012)
  37. Targeting the epigenetic regulation of antitumour immunity. Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Nat Rev Drug Discov 19 776-800 (2020)
  38. BET inhibitors: a novel epigenetic approach. Doroshow DB, Eder JP, LoRusso PM. Ann Oncol 28 1776-1787 (2017)
  39. Emerging treatment strategies for glioblastoma multiforme. Carlsson SK, Brothers SP, Wahlestedt C. EMBO Mol Med 6 1359-1370 (2014)
  40. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Wilting RH, Dannenberg JH. Drug Resist Updat 15 21-38 (2012)
  41. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity. Wainwright EN, Scaffidi P. Trends Cancer 3 372-386 (2017)
  42. Marked for death: targeting epigenetic changes in cancer. Pfister SX, Ashworth A. Nat Rev Drug Discov 16 241-263 (2017)
  43. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Gjertsen BT, Schöffski P. Leukemia 29 11-19 (2015)
  44. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Taniguchi Y. Int J Mol Sci 17 E1849 (2016)
  45. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T, Senzer N, Nemunaitis J. Future Sci OA 5 FSO372 (2019)
  46. Clinical trials for BET inhibitors run ahead of the science. Andrieu G, Belkina AC, Denis GV. Drug Discov Today Technol 19 45-50 (2016)
  47. Bromodomain inhibitors and cancer therapy: From structures to applications. Pérez-Salvia M, Esteller M. Epigenetics 12 323-339 (2017)
  48. ATAC-king the complexity of SAGA during evolution. Spedale G, Timmers HT, Pijnappel WW. Genes Dev 26 527-541 (2012)
  49. Emerging targeted agents in metastatic breast cancer. Zardavas D, Baselga J, Piccart M. Nat Rev Clin Oncol 10 191-210 (2013)
  50. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Fu LL, Tian M, Li X, Li JJ, Huang J, Ouyang L, Zhang Y, Liu B. Oncotarget 6 5501-5516 (2015)
  51. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Bauer DE, Kamran SC, Orkin SH. Blood 120 2945-2953 (2012)
  52. Achieving clinical success with BET inhibitors as anti-cancer agents. Shorstova T, Foulkes WD, Witcher M. Br J Cancer 124 1478-1490 (2021)
  53. Targeting protein-protein interaction by small molecules. Jin L, Wang W, Fang G. Annu Rev Pharmacol Toxicol 54 435-456 (2014)
  54. Metabolic reprogramming and epigenetic modifications on the path to cancer. Sun L, Zhang H, Gao P. Protein Cell 13 877-919 (2022)
  55. Targeting tumour-supportive cellular machineries in anticancer drug development. Dobbelstein M, Moll U. Nat Rev Drug Discov 13 179-196 (2014)
  56. Emerging therapeutic drugs for AML. Stein EM, Tallman MS. Blood 127 71-78 (2016)
  57. Chromatin contributions to the regulation of innate immunity. Smale ST, Tarakhovsky A, Natoli G. Annu Rev Immunol 32 489-511 (2014)
  58. Targeting Cancer Cells with BET Bromodomain Inhibitors. Xu Y, Vakoc CR. Cold Spring Harb Perspect Med 7 a026674 (2017)
  59. Drug Discovery Targeting Bromodomain-Containing Protein 4. Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J. J Med Chem 60 4533-4558 (2017)
  60. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Chaidos A, Caputo V, Karadimitris A. Ther Adv Hematol 6 128-141 (2015)
  61. Targeting Epigenetics in Cancer. Bennett RL, Licht JD. Annu Rev Pharmacol Toxicol 58 187-207 (2018)
  62. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Genome Med 7 129 (2015)
  63. Targeting BET bromodomains for cancer treatment. Jung M, Gelato KA, Fernández-Montalván A, Siegel S, Haendler B. Epigenomics 7 487-501 (2015)
  64. Recent advances in acute myeloid leukemia stem cell biology. Horton SJ, Huntly BJ. Haematologica 97 966-974 (2012)
  65. Regulatory Enhancer-Core-Promoter Communication via Transcription Factors and Cofactors. Zabidi MA, Stark A. Trends Genet 32 801-814 (2016)
  66. Tudor: a versatile family of histone methylation 'readers'. Lu R, Wang GG. Trends Biochem Sci 38 546-555 (2013)
  67. CDK9: a signaling hub for transcriptional control. Bacon CW, D'Orso I. Transcription 10 57-75 (2019)
  68. Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathways. Liu X, Kraus WL, Bai X. Trends Biochem Sci 40 516-525 (2015)
  69. Bromodomain biology and drug discovery. Zaware N, Zhou MM. Nat Struct Mol Biol 26 870-879 (2019)
  70. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. Campbell RM, Tummino PJ. J Clin Invest 124 64-69 (2014)
  71. Mass spectrometry-based proteomics in preclinical drug discovery. Schirle M, Bantscheff M, Kuster B. Chem Biol 19 72-84 (2012)
  72. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Brien GL, Valerio DG, Armstrong SA. Cancer Cell 29 464-476 (2016)
  73. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. Bennett RL, Swaroop A, Troche C, Licht JD. Cold Spring Harb Perspect Med 7 a026708 (2017)
  74. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. Gu S, Cui D, Chen X, Xiong X, Zhao Y. Bioessays 40 e1700247 (2018)
  75. Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer. Gong F, Chiu LY, Miller KM. PLoS Genet 12 e1006272 (2016)
  76. Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb. C Quaresma AJ, Bugai A, Barboric M. Nucleic Acids Res 44 7527-7539 (2016)
  77. Bromodomain 4: a cellular Swiss army knife. Devaiah BN, Gegonne A, Singer DS. J Leukoc Biol 100 679-686 (2016)
  78. BET bromodomain inhibitors: a patent review. Garnier JM, Sharp PP, Burns CJ. Expert Opin Ther Pat 24 185-199 (2014)
  79. Mouse models of MLL leukemia: recapitulating the human disease. Milne TA. Blood 129 2217-2223 (2017)
  80. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Winer ES, Stone RM. Ther Adv Hematol 10 2040620719860645 (2019)
  81. The enigmatic role of H2Bub1 in cancer. Johnsen SA. FEBS Lett 586 1592-1601 (2012)
  82. Bromodomains and their pharmacological inhibitors. Gallenkamp D, Gelato KA, Haendler B, Weinmann H. ChemMedChem 9 438-464 (2014)
  83. Chromatin deregulation in disease. Mirabella AC, Foster BM, Bartke T. Chromosoma 125 75-93 (2016)
  84. Super-enhancer function and its application in cancer targeted therapy. Tang F, Yang Z, Tan Y, Li Y. NPJ Precis Oncol 4 2 (2020)
  85. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. Borck PC, Guo LW, Plutzky J. Circ Res 126 1190-1208 (2020)
  86. Two faces of brd4: mitotic bookmark and transcriptional lynchpin. Devaiah BN, Singer DS. Transcription 4 13-17 (2013)
  87. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Wadhwa E, Nicolaides T. Cureus 8 e620 (2016)
  88. Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Simó-Riudalbas L, Esteller M. Br J Pharmacol 172 2716-2732 (2015)
  89. Epigenetics in Cancer: A Hematological Perspective. Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. PLoS Genet 12 e1006193 (2016)
  90. Bromodomain Histone Readers and Cancer. Jain AK, Barton MC. J Mol Biol 429 2003-2010 (2017)
  91. Chemoproteomic approaches to drug target identification and drug profiling. Bantscheff M, Drewes G. Bioorg Med Chem 20 1973-1978 (2012)
  92. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Neff T, Armstrong SA. Blood 121 4847-4853 (2013)
  93. Unravelling the genomic targets of small molecules using high-throughput sequencing. Rodriguez R, Miller KM. Nat Rev Genet 15 783-796 (2014)
  94. Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Chen R, Yik JH, Lew QJ, Chao SH. Biomed Res Int 2014 232870 (2014)
  95. Epigenetic Regulation of Monocyte and Macrophage Function. Hoeksema MA, de Winther MP. Antioxid Redox Signal 25 758-774 (2016)
  96. A chemical probe toolbox for dissecting the cancer epigenome. Shortt J, Ott CJ, Johnstone RW, Bradner JE. Nat Rev Cancer 17 160-183 (2017)
  97. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases. Padmanabhan B, Mathur S, Manjula R, Tripathi S. J Biosci 41 295-311 (2016)
  98. DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies. Pechalrieu D, Etievant C, Arimondo PB. Biochem Pharmacol 129 1-13 (2017)
  99. In focus: MLL-rearranged leukemia. de Boer J, Walf-Vorderwülbecke V, Williams O. Leukemia 27 1224-1228 (2013)
  100. Beyond receptors and signaling: epigenetic factors in the regulation of innate immunity. Mehta S, Jeffrey KL. Immunol Cell Biol 93 233-244 (2015)
  101. Bromodomains as therapeutic targets in cancer. Barbieri I, Cannizzaro E, Dawson MA. Brief Funct Genomics 12 219-230 (2013)
  102. Cell signaling and cancer: a mechanistic insight into drug resistance. Panda M, Biswal BK. Mol Biol Rep 46 5645-5659 (2019)
  103. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Greenblatt SM, Nimer SD. Leukemia 28 1396-1406 (2014)
  104. Epigenetic polypharmacology: from combination therapy to multitargeted drugs. de Lera AR, Ganesan A. Clin Epigenetics 8 105 (2016)
  105. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. Kulikowski E, Rakai BD, Wong NCW. Med Res Rev 41 223-245 (2021)
  106. Constitutive NF-κB activation in AML: Causes and treatment strategies. Bosman MC, Schuringa JJ, Vellenga E. Crit Rev Oncol Hematol 98 35-44 (2016)
  107. Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation. Falvo JV, Jasenosky LD, Kruidenier L, Goldfeld AE. Adv Immunol 118 37-128 (2013)
  108. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Deshpande AJ, Bradner J, Armstrong SA. Trends Immunol 33 563-570 (2012)
  109. Epigenome-based personalized medicine in human cancer. Yan W, Herman JG, Guo M. Epigenomics 8 119-133 (2016)
  110. Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin. Bochyńska A, Lüscher-Firzlaff J, Lüscher B. Cells 7 E17 (2018)
  111. The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. Berkovits BD, Wolgemuth DJ. Curr Top Dev Biol 102 293-326 (2013)
  112. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Kim TK, Gore SD, Zeidan AM. Semin Hematol 52 172-183 (2015)
  113. Epigenetics in the hematologic malignancies. Fong CY, Morison J, Dawson MA. Haematologica 99 1772-1783 (2014)
  114. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. J Hematol Oncol 14 121 (2021)
  115. Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. Jia Y, Chng WJ, Zhou J. J Hematol Oncol 12 77 (2019)
  116. Disordered epigenetic regulation in MLL-related leukemia. Zhang Y, Chen A, Yan XM, Huang G. Int J Hematol 96 428-437 (2012)
  117. Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Krivtsov AV, Hoshii T, Armstrong SA. Cold Spring Harb Perspect Med 7 a026658 (2017)
  118. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Li BE, Ernst P. Exp Hematol 42 995-1012 (2014)
  119. Epigenetics and inheritance of phenotype variation in livestock. Triantaphyllopoulos KA, Ikonomopoulos I, Bannister AJ. Epigenetics Chromatin 9 31 (2016)
  120. FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways. Kelleher FC, O'Sullivan H. Oncotarget 7 42792-42804 (2016)
  121. Epigenetic alterations in hematopoietic malignancies. Chung YR, Schatoff E, Abdel-Wahab O. Int J Hematol 96 413-427 (2012)
  122. Targeting epigenetic regulations in cancer. Ning B, Li W, Zhao W, Wang R. Acta Biochim Biophys Sin (Shanghai) 48 97-109 (2016)
  123. Current understanding of the role of the Brd4 protein in the papillomavirus lifecycle. McBride AA, Jang MK. Viruses 5 1374-1394 (2013)
  124. Epigenetic drugs against cancer: an evolving landscape. Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Arch Toxicol 88 1651-1668 (2014)
  125. Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Bewersdorf JP, Shallis R, Stahl M, Zeidan AM. Ther Adv Hematol 10 2040620718816698 (2019)
  126. Molecular processes involved in B cell acute lymphoblastic leukaemia. Malouf C, Ottersbach K. Cell Mol Life Sci 75 417-446 (2018)
  127. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. Chan AKN, Chen CW. Front Cell Dev Biol 7 81 (2019)
  128. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia. van Gils N, Denkers F, Smit L. Front Oncol 11 659253 (2021)
  129. The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Cheung KL, Kim C, Zhou MM. Front Mol Biosci 8 728777 (2021)
  130. The emerging role of mass spectrometry-based proteomics in drug discovery. Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. Nat Rev Drug Discov 21 637-654 (2022)
  131. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Abedin SM, Boddy CS, Munshi HG. Onco Targets Ther 9 5943-5953 (2016)
  132. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Cai SF, Chen CW, Armstrong SA. Mol Cell 60 561-570 (2015)
  133. -7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity. Honda H, Nagamachi A, Inaba T. Oncogene 34 2413-2425 (2015)
  134. Biological function and histone recognition of family IV bromodomain-containing proteins. Lloyd JT, Glass KC. J Cell Physiol 233 1877-1886 (2018)
  135. Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. Lu B, Huang X, Mo J, Zhao W. Front Pharmacol 7 84 (2016)
  136. Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. Sun Y, Chen BR, Deshpande A. Front Oncol 8 41 (2018)
  137. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Tsai CT, So CW. Oncogene 36 1753-1759 (2017)
  138. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Curr Pharm Des 19 578-613 (2013)
  139. Targeting smooth muscle cell phenotypic switching in vascular disease. Chakraborty R, Chatterjee P, Dave JM, Ostriker AC, Greif DM, Rzucidlo EM, Martin KA. JVS Vasc Sci 2 79-94 (2021)
  140. Bromodomain proteins: repairing DNA damage within chromatin. Chiu LY, Gong F, Miller KM. Philos Trans R Soc Lond B Biol Sci 372 20160286 (2017)
  141. Neuroblastoma and the epigenome. Fetahu IS, Taschner-Mandl S. Cancer Metastasis Rev 40 173-189 (2021)
  142. Epigenetics: A primer for clinicians. Paluch BE, Naqash AR, Brumberger Z, Nemeth MJ, Griffiths EA. Blood Rev 30 285-295 (2016)
  143. Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Cierpicki T, Grembecka J. Immunol Rev 263 279-301 (2015)
  144. The Impact of External Factors on the Epigenome: In Utero and over Lifetime. Toraño EG, García MG, Fernández-Morera JL, Niño-García P, Fernández AF. Biomed Res Int 2016 2568635 (2016)
  145. Treatment of infant leukemias: challenge and promise. Brown P. Hematology Am Soc Hematol Educ Program 2013 596-600 (2013)
  146. Bromodomain proteins in HIV infection. Boehm D, Conrad RJ, Ott M. Viruses 5 1571-1586 (2013)
  147. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Pastore F, Levine RL. Haematologica 101 269-278 (2016)
  148. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Gallipoli P, Giotopoulos G, Huntly BJ. Ther Adv Hematol 6 103-119 (2015)
  149. Targeting Super-Enhancers as a Therapeutic Strategy for Cancer Treatment. He Y, Long W, Liu Q. Front Pharmacol 10 361 (2019)
  150. The role of chromatin modifiers in normal and malignant hematopoiesis. Butler JS, Dent SY. Blood 121 3076-3084 (2013)
  151. Using Chemical Epigenetics to Target Cancer. Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi J. Mol Cell 78 1086-1095 (2020)
  152. Differentiation therapy of myeloid leukemia: four decades of development. Madan V, Koeffler HP. Haematologica 106 26-38 (2021)
  153. Epigenetic regulation of cardiac fibrosis. Stratton MS, McKinsey TA. J Mol Cell Cardiol 92 206-213 (2016)
  154. From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions. Wu M, Shen J. Front Oncol 9 1307 (2019)
  155. Supercharging BRD4 with NUT in carcinoma. Eagen KP, French CA. Oncogene 40 1396-1408 (2021)
  156. BET bromodomain inhibitors in leukemia. Basheer F, Huntly BJ. Exp Hematol 43 718-731 (2015)
  157. RNA-Binding Proteins in Acute Leukemias. Schuschel K, Helwig M, Hüttelmaier S, Heckl D, Klusmann JH, Hoell JI. Int J Mol Sci 21 E3409 (2020)
  158. Targeting cancer epigenetics: Linking basic biology to clinical medicine. Shinjo K, Kondo Y. Adv Drug Deliv Rev 95 56-64 (2015)
  159. Privileged diazepine compounds and their emergence as bromodomain inhibitors. Smith SG, Sanchez R, Zhou MM. Chem Biol 21 573-583 (2014)
  160. Targeting transcription cycles in cancer. Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Nat Rev Cancer 22 5-24 (2022)
  161. Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies. Maury E, Hashizume R. Epigenetics 12 353-369 (2017)
  162. Proteomics in epigenetics: new perspectives for cancer research. Bartke T, Borgel J, DiMaggio PA. Brief Funct Genomics 12 205-218 (2013)
  163. Epigenetic Strategies to Boost Cancer Immunotherapies. Barrero MJ. Int J Mol Sci 18 E1108 (2017)
  164. Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. Hashizume R. Neurol Med Chir (Tokyo) 57 331-342 (2017)
  165. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications. Reyes-Garau D, Ribeiro ML, Roué G. Cancers (Basel) 11 E1483 (2019)
  166. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Liu WJ, Tan XH, Luo XP, Guo BP, Wei ZJ, Ke Q, He S, Cen H. Leuk Lymphoma 55 2691-2698 (2014)
  167. Small-molecular modulators of cancer-associated epigenetic mechanisms. Itoh Y, Suzuki T, Miyata N. Mol Biosyst 9 873-896 (2013)
  168. Targeting bromodomain and extraterminal proteins in breast cancer. Sahni JM, Keri RA. Pharmacol Res 129 156-176 (2018)
  169. Chromatin-regulating proteins as targets for cancer therapy. Oike T, Ogiwara H, Amornwichet N, Nakano T, Kohno T. J Radiat Res 55 613-628 (2014)
  170. Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Puła B, Gołos A, Górniak P, Jamroziak K. Cancers (Basel) 11 E1834 (2019)
  171. Progress in the Development of non-BET Bromodomain Chemical Probes. Theodoulou NH, Tomkinson NC, Prinjha RK, Humphreys PG. ChemMedChem 11 477-487 (2016)
  172. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway. Fung TK, Gandillet A, So CW. Curr Opin Hematol 19 280-286 (2012)
  173. The therapeutic potential of epigenetic manipulation during infectious diseases. Cole J, Morris P, Morris P, Dickman MJ, Dockrell DH. Pharmacol Ther 167 85-99 (2016)
  174. BET inhibitors in cancer therapeutics: a patent review. Ghoshal A, Yugandhar D, Srivastava AK. Expert Opin Ther Pat 26 505-522 (2016)
  175. BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. Andrieu GP, Shafran JS, Deeney JT, Bharadwaj KR, Rangarajan A, Denis GV. J Leukoc Biol 104 265-274 (2018)
  176. Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development. Jeffers V, Yang C, Huang S, Sullivan WJ. Microbiol Mol Biol Rev 81 e00047-16 (2017)
  177. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Anshabo AT, Milne R, Wang S, Albrecht H. Front Oncol 11 678559 (2021)
  178. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Tanaka M, Roberts JM, Qi J, Bradner JE. Pharm Pat Anal 4 261-284 (2015)
  179. Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Yang AY, Kim H, Li W, Kong AN. Curr Top Med Chem 16 697-713 (2016)
  180. Somatic alterations and dysregulation of epigenetic modifiers in cancers. Aumann S, Abdel-Wahab O. Biochem Biophys Res Commun 455 24-34 (2014)
  181. The complex activities of the SET1/MLL complex core subunits in development and disease. Jiang H. Biochim Biophys Acta Gene Regul Mech 1863 194560 (2020)
  182. The contribution of mass spectrometry-based proteomics to understanding epigenetics. Noberini R, Sigismondo G, Bonaldi T. Epigenomics 8 429-445 (2016)
  183. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Blancafort P, Jin J, Frye S. Mol Pharmacol 83 563-576 (2013)
  184. Enhancer dysfunction in leukemia. Bhagwat AS, Lu B, Vakoc CR. Blood 131 1795-1804 (2018)
  185. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Gambacorta V, Gnani D, Vago L, Di Micco R. Front Cell Dev Biol 7 207 (2019)
  186. MLL leukemia and future treatment strategies. Marschalek R. Arch Pharm (Weinheim) 348 221-228 (2015)
  187. Mechanisms of epigenetic regulation of leukemia onset and progression. Ntziachristos P, Mullenders J, Trimarchi T, Aifantis I. Adv Immunol 117 1-38 (2013)
  188. Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer. Benton CB, Fiskus W, Bhalla KN. Cancer J 23 286-291 (2017)
  189. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C. Endocr Relat Cancer 28 T51-T66 (2021)
  190. Chromatin targeting drugs in cancer and immunity. Prinjha R, Tarakhovsky A. Genes Dev 27 1731-1738 (2013)
  191. How to effectively treat acute leukemia patients bearing MLL-rearrangements ? Steinhilber D, Marschalek R. Biochem Pharmacol 147 183-190 (2018)
  192. Menin as a hub controlling mixed lineage leukemia. Thiel AT, Huang J, Lei M, Hua X. Bioessays 34 771-780 (2012)
  193. Design of small molecule epigenetic modulators. Pachaiyappan B, Woster PM. Bioorg Med Chem Lett 24 21-32 (2014)
  194. Epigenetic chemical probes. Müller S, Brown PJ. Clin Pharmacol Ther 92 689-693 (2012)
  195. Functional Roles of Bromodomain Proteins in Cancer. Boyson SP, Gao C, Quinn K, Boyd J, Paculova H, Frietze S, Glass KC. Cancers (Basel) 13 3606 (2021)
  196. Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia. Kumar S, Nagpal R, Kumar A, Ashraf MU, Bae YS. Biomedicines 9 690 (2021)
  197. P-TEFb as A Promising Therapeutic Target. Fujinaga K. Molecules 25 E838 (2020)
  198. Targeting of epigenetic regulators in neuroblastoma. Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R, Roma J, Toledo JS, Gallego S, Segura MF. Exp Mol Med 50 1-12 (2018)
  199. CDK9 keeps RNA polymerase II on track. Egloff S. Cell Mol Life Sci 78 5543-5567 (2021)
  200. From histones to RNA: role of methylation in cancer. Xhemalce B. Brief Funct Genomics 12 244-253 (2013)
  201. Mass spectrometry approaches to monitor protein-drug interactions. Zinn N, Hopf C, Drewes G, Bantscheff M. Methods 57 430-440 (2012)
  202. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia. Lu R, Wang GG. Front Oncol 7 241 (2017)
  203. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Ribeiro ML, Reyes-Garau D, Armengol M, Fernández-Serrano M, Roué G. Front Genet 10 986 (2019)
  204. Selective targeting of epigenetic reader domains. Greschik H, Schüle R, Günther T. Expert Opin Drug Discov 12 449-463 (2017)
  205. The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia. Roe JS, Vakoc CR. Cold Spring Harb Symp Quant Biol 81 61-66 (2016)
  206. The rocky road to personalized medicine in acute myeloid leukaemia. Brinda B, Khan I, Parkin B, Konig H. J Cell Mol Med 22 1411-1427 (2018)
  207. Chemical proteomic strategies for the discovery and development of anticancer drugs. Liu Y, Guo M. Proteomics 14 399-411 (2014)
  208. Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Fratta E, Montico B, Rizzo A, Colizzi F, Sigalotti L, Dolcetti R. Oncotarget 7 57327-57350 (2016)
  209. RNA-modifying enzymes and their function in a chromatin context. Tzelepis K, Rausch O, Kouzarides T. Nat Struct Mol Biol 26 858-862 (2019)
  210. The emerging role of BET inhibitors in breast cancer. Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. Breast 53 152-163 (2020)
  211. Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Klobuch S, Thomas S, Pukrop T, Hackl C, Herr W, Ghibelli L, Gerner C, Reichle A. Front Pharmacol 9 1357 (2018)
  212. Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer. Fairlie WD, Lee EF. Int J Mol Sci 22 2841 (2021)
  213. DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Bhattacharjee D, Shenoy S, Bairy KL. Scientifica (Cairo) 2016 6072357 (2016)
  214. Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. Tough DF, Lewis HD, Rioja I, Lindon MJ, Prinjha RK. Br J Pharmacol 171 4981-5010 (2014)
  215. MYC's Fine Line Between B Cell Development and Malignancy. de Barrios O, Meler A, Parra M. Cells 9 E523 (2020)
  216. BET Proteins as Attractive Targets for Cancer Therapeutics. Sarnik J, Popławski T, Tokarz P. Int J Mol Sci 22 11102 (2021)
  217. Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers. Eguchi A, Lee GO, Wan F, Erwin GS, Ansari AZ. Biochem J 462 397-413 (2014)
  218. Gene Transactivation and Transrepression in MYC-Driven Cancers. Scafuro M, Capasso L, Carafa V, Altucci L, Nebbioso A. Int J Mol Sci 22 3458 (2021)
  219. Mixed lineage leukemia protein in normal and leukemic stem cells. Yip BH, So CW. Exp Biol Med (Maywood) 238 315-323 (2013)
  220. Mutual relationships between transcription and pre-mRNA processing in the synthesis of mRNA. Lenasi T, Barboric M. Wiley Interdiscip Rev RNA 4 139-154 (2013)
  221. Novel epigenetic therapies in hematological malignancies: Current status and beyond. Gallipoli P, Huntly BJP. Semin Cancer Biol 51 198-210 (2018)
  222. Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. Jennings LE, Measures AR, Wilson BG, Conway SJ. Future Med Chem 6 179-204 (2014)
  223. Protein-protein interaction inhibitors: advances in anticancer drug design. Ferreira LG, Oliva G, Andricopulo AD. Expert Opin Drug Discov 11 957-968 (2016)
  224. Recent progress in the treatment of infant acute lymphoblastic leukemia. Tomizawa D. Pediatr Int 57 811-819 (2015)
  225. Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis. Poreba E, Lesniewicz K, Durzynska J. Int J Mol Sci 21 E9340 (2020)
  226. Epigenetic Regulation of Inflammatory Signaling and Inflammation-Induced Cancer. Tan SYX, Zhang J, Tee WW. Front Cell Dev Biol 10 931493 (2022)
  227. Erythropoiesis provides a BRD's eye view of BET protein function. Stonestrom AJ, Hsu SC, Werner MT, Blobel GA. Drug Discov Today Technol 19 23-28 (2016)
  228. Minireview: Conversing with chromatin: the language of nuclear receptors. Biddie SC, John S. Mol Endocrinol 28 3-15 (2014)
  229. Process of Fragment-Based Lead Discovery-A Perspective from NMR. Ma R, Wang P, Wu J, Ruan K. Molecules 21 E854 (2016)
  230. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. Yi Y, Ge S. J Hematol Oncol 15 35 (2022)
  231. Therapeutic targeting of immune checkpoints with small molecule inhibitors. Smith WM, Purvis IJ, Bomstad CN, Labak CM, Velpula KK, Tsung AJ, Regan JN, Venkataraman S, Vibhakar R, Asuthkar S. Am J Transl Res 11 529-541 (2019)
  232. A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers. Shin DG, Bayarsaihan D. Yale J Biol Med 90 63-71 (2017)
  233. Current and potential epigenetic targets in multiple myeloma. Pawlyn C, Kaiser MF, Davies FE, Morgan GJ. Epigenomics 6 215-228 (2014)
  234. Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies. Buisman SC, de Haan G. Cells 8 E868 (2019)
  235. Epigenetic Regulation: A Link between Inflammation and Carcinogenesis. Vezzani B, Carinci M, Previati M, Giacovazzi S, Della Sala M, Gafà R, Lanza G, Wieckowski MR, Pinton P, Giorgi C. Cancers (Basel) 14 1221 (2022)
  236. Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Ballabio E, Milne TA. Mol Cell Oncol 1 e955330 (2014)
  237. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Bouligny IM, Maher KR, Grant S. Blood Rev 57 100996 (2023)
  238. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Hou HA, Tien HF. Expert Rev Hematol 9 447-469 (2016)
  239. NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics. Moreno V, Saluja K, Pina-Oviedo S. Front Oncol 12 860830 (2022)
  240. Studying epigenetic complexes and their inhibitors with the proteomics toolbox. Weigt D, Hopf C, Médard G. Clin Epigenetics 8 76 (2016)
  241. Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. Perner F, Armstrong SA. Cells 9 E2721 (2020)
  242. Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer. Okabe A, Kaneda A. Cancer Sci 112 2081-2088 (2021)
  243. A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles. Ali HA, Li Y, Bilal AHM, Qin T, Yuan Z, Zhao W. Front Pharmacol 13 818891 (2022)
  244. CRISPR-based reagents to study the influence of the epigenome on gene expression. Lavender P, Lavender P, Kelly A, Hendy E, McErlean P. Clin Exp Immunol 194 9-16 (2018)
  245. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets. Reikvam H, Hoang TT, Bruserud Ø. Expert Rev Hematol 8 315-327 (2015)
  246. Epigenetics and blood disorders. Scholz B, Marschalek R. Br J Haematol 158 307-322 (2012)
  247. Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia. Xu H, Yu H, Jin R, Wu X, Chen H. Cells 10 3349 (2021)
  248. Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer. Taylor-Papadimitriou J, Burchell JM. Cells 11 1113 (2022)
  249. Long Non-coding RNAs as Functional and Structural Chromatin Modulators in Acute Myeloid Leukemia. Wurm AA, Pina C. Front Oncol 9 899 (2019)
  250. MicroRNAs mark in the MLL-rearranged leukemia. Benetatos L, Vartholomatos G. Ann Hematol 92 1439-1450 (2013)
  251. Relevance of BET Family Proteins in SARS-CoV-2 Infection. Lara-Ureña N, García-Domínguez M. Biomolecules 11 1126 (2021)
  252. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib. Liu L, Shi B, Wang X, Xiang H. Future Med Chem 10 343-356 (2018)
  253. Targeting "undruggable" c-Myc protein by synthetic lethality. Wang C, Fang H, Zhang J, Gu Y. Front Med 15 541-550 (2021)
  254. Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off? Groves IJ, Sinclair JH, Wills MR. Front Cell Infect Microbiol 10 329 (2020)
  255. Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. Maher M, Diesch J, Le Pannérer MM, Buschbeck M. Cancers (Basel) 13 1746 (2021)
  256. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. Grieselhuber NR, Mims AS. Curr Hematol Malig Rep 16 192-206 (2021)
  257. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Stahl M, Lu BY, Kim TK, Zeidan AM. Target Oncol 12 413-447 (2017)
  258. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. Waibel M, Gregory G, Shortt J, Johnstone RW. Curr Opin Hematol 21 297-308 (2014)
  259. Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives. Ghiboub M, Elfiky AMI, de Winther MPJ, Harker NR, Tough DF, de Jonge WJ. J Pers Med 11 336 (2021)
  260. The Intersection of Structural and Chemical Biology - An Essential Synergy. Zuercher WJ, Elkins JM, Knapp S. Cell Chem Biol 23 173-182 (2016)
  261. The role of enhancer RNAs in epigenetic regulation of gene expression. Rahnamoun H, Orozco P, Lauberth SM. Transcription 11 19-25 (2020)
  262. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. Komatsubara KM, Jeter J, Carvajal RD, Margolin K, Schadendorf D, Hauschild A. Am Soc Clin Oncol Educ Book 37 641-650 (2017)
  263. Histone Modifications and Their Targeting in Lymphoid Malignancies. Fernández-Serrano M, Winkler R, Santos JC, Le Pannérer MM, Buschbeck M, Roué G. Int J Mol Sci 23 253 (2021)
  264. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. Lee E, Koh Y, Hong J, Eom HS, Yoon SS. J Korean Med Sci 36 e85 (2021)
  265. Targeting Epigenetic 'Readers' with Natural Compounds for Cancer Interception. Damiani E, Duran MN, Mohan N, Rajendran P, Dashwood RH. J Cancer Prev 25 189-203 (2020)
  266. The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. Fan HC, Chi CS, Chang YK, Tung MC, Lin SZ, Harn HJ. Int J Mol Sci 19 E395 (2018)
  267. The role of protein acetylation in carcinogenesis and targeted drug discovery. Yang J, Song C, Zhan X. Front Endocrinol (Lausanne) 13 972312 (2022)
  268. BETting on a Transcriptional Deficit as the Main Cause for Cornelia de Lange Syndrome. García-Gutiérrez P, García-Domínguez M. Front Mol Biosci 8 709232 (2021)
  269. BRD4: a general regulator of transcription elongation. Altendorfer E, Mochalova Y, Mayer A. Transcription 13 70-81 (2022)
  270. Chemical genetics and its potential in cardiac stem cell therapy. Vieira JM, Riley PR. Br J Pharmacol 169 318-327 (2013)
  271. Chemogenomics for drug discovery: clinical molecules from open access chemical probes. Quinlan RBA, Brennan PE. RSC Chem Biol 2 759-795 (2021)
  272. Current strategies and progress for targeting the "undruggable" transcription factors. Zhuang JJ, Liu Q, Wu DL, Tie L. Acta Pharmacol Sin 43 2474-2481 (2022)
  273. Enhancer rewiring in tumors: an opportunity for therapeutic intervention. Richart L, Bidard FC, Margueron R. Oncogene 40 3475-3491 (2021)
  274. Insights into novel emerging epigenetic drugs in myeloid malignancies. Chandhok NS, Prebet T. Ther Adv Hematol 10 2040620719866081 (2019)
  275. Pharmacological Modulation of Transcriptional Coregulators in Cancer. Bishop TR, Zhang Y, Erb MA. Trends Pharmacol Sci 40 388-402 (2019)
  276. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase. Rathert P. Life (Basel) 11 726 (2021)
  277. Targeted therapy of acute myeloid leukemia. Carneiro BA, Altman JK, Kaplan JB, Ossenkoppele G, Swords R, Platanias LC, Giles FJ. Expert Rev Anticancer Ther 15 399-413 (2015)
  278. Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers. Fairlie WD, Lee EF. Biochem Soc Trans 49 2397-2410 (2021)
  279. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B. Int J Mol Sci 23 10957 (2022)
  280. Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia. Xu X, Schneider B. Cell Oncol (Dordr) 42 117-130 (2019)
  281. 'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia. Brumatti G, Lalaoui N, Wei AH, Silke J. Trends Mol Med 23 264-281 (2017)
  282. Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins. Lai J, Liu Z, Zhao Y, Ma C, Huang H. Front Oncol 11 716830 (2021)
  283. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. Miyamoto K, Minami Y. Int J Mol Sci 21 E5114 (2020)
  284. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. Okosun J, Packham G, Fitzgibbon J. Expert Opin Investig Drugs 23 1321-1332 (2014)
  285. New Drugs Bringing New Challenges to AML: A Brief Review. Yeoh ZH, Bajel A, Wei AH. J Pers Med 11 1003 (2021)
  286. Review: Enhancers in Autoimmune Arthritis: Implications and Therapeutic Potential. Peeters JGC, Vastert SJ, van Wijk F, van Loosdregt J. Arthritis Rheumatol 69 1925-1936 (2017)
  287. The emerging field of chemo- and pharmacoproteomics. Hess S. Proteomics Clin Appl 7 171-180 (2013)
  288. Combinatorial Use of Both Epigenetic and Non-Epigenetic Mechanisms to Efficiently Reactivate HIV Latency. Hokello J, Sharma AL, Tyagi M. Int J Mol Sci 22 3697 (2021)
  289. Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia. Xu H, Wen Y, Jin R, Chen H. Front Pediatr 10 975819 (2022)
  290. Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family. Radwan M, Serya R. Arch Pharm (Weinheim) 350 (2017)
  291. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond. Feng J, Meng X. Front Pharmacol 13 946811 (2022)
  292. Regulation of programmed cell death by Brd4. Hu J, Pan D, Li G, Chen K, Hu X. Cell Death Dis 13 1059 (2022)
  293. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia. Porazzi P, De Dominici M, Salvino J, Calabretta B. Genes (Basel) 12 1355 (2021)
  294. Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia. Liu Q, Garcia M, Wang S, Chen CW. Cells 9 E1888 (2020)
  295. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, Lou G, Yang C. Signal Transduct Target Ther 8 420 (2023)
  296. Enhancing venetoclax activity in hematological malignancies. Satta T, Grant S. Expert Opin Investig Drugs 29 697-708 (2020)
  297. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. Markouli M, Strepkos D, Piperi C. Int J Mol Sci 23 13657 (2022)
  298. Murine Models of Acute Myeloid Leukemia. Kurtz KJ, Conneely SE, O'Keefe M, Wohlan K, Rau RE. Front Oncol 12 854973 (2022)
  299. Recent progress and structural analyses of domain-selective BET inhibitors. Divakaran A, Harki DA, Pomerantz WCK. Med Res Rev 43 972-1018 (2023)
  300. The molecular understanding of super-enhancer dysregulation in cancer. Yoshino S, Suzuki HI. Nagoya J Med Sci 84 216-229 (2022)
  301. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias. Banday S, Farooq Z, Ganai SA, Altaf M. Clin Epigenetics 12 73 (2020)
  302. Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies. Xiao R, Wang H, Liang K. Blood Sci 1 50-56 (2019)
  303. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. To KKW, Xing E, Larue RC, Li PK. Molecules 28 3043 (2023)
  304. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations. Ma T, Chen Y, Yi ZG, Li YH, Bai J, Li LJ, Zhang LS. Genes Dis 10 2306-2319 (2023)
  305. Bromodomain inhibitors and therapeutic applications. Gajjela BK, Zhou MM. Curr Opin Chem Biol 75 102323 (2023)
  306. Catching BETs by viruses. Zandian M, Chen IP, Byrareddy SN, Fujimori DG, Ott M, Kutateladze TG. Biochim Biophys Acta Gene Regul Mech 1865 194859 (2022)
  307. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. Walsh L, Gallagher WM, O'Connor DP, Ní Chonghaile T. Expert Rev Mol Diagn 16 541-551 (2016)
  308. Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment. Mohammad A, Jha S. Cancers (Basel) 15 215 (2022)
  309. Novel approaches to pediatric leukemia treatment. Thomas X. Expert Rev Anticancer Ther 15 811-828 (2015)
  310. R-Loops and R-Loop-Binding Proteins in Cancer Progression and Drug Resistance. Elsakrmy N, Cui H. Int J Mol Sci 24 7064 (2023)
  311. Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy. Gargano D, Segatto M, Di Bartolomeo S. Int J Mol Sci 24 5665 (2023)
  312. Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases. Wu D, Duan Q. Pharmaceuticals (Basel) 15 1032 (2022)
  313. Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies. Shi Y, Wang M, Liu D, Ullah S, Ma X, Yang H, Liu B. Front Oncol 12 1036648 (2022)
  314. Targeting the Transcriptome Through Globally Acting Components. Parrello D, Vlasenok M, Kranz L, Nechaev S. Front Genet 12 749850 (2021)
  315. The role of histone modifications in leukemogenesis. Birch NW, Shilatifard A. J Biosci 45 6 (2020)
  316. Transcription Pause and Escape in Neurodevelopmental Disorders. Eigenhuis KN, Somsen HB, van den Berg DLC. Front Neurosci 16 846272 (2022)
  317. Transcription factor networks link B-lymphocyte development and malignant transformation in leukemia. Sigvardsson M. Genes Dev 37 703-723 (2023)
  318. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think. Weissmiller AM, Fesik SW, Tansey WP. J Clin Med 13 274 (2024)

Articles citing this publication (587)

  1. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Cell 153 320-334 (2013)
  2. Histone recognition and large-scale structural analysis of the human bromodomain family. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Müller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. Cell 149 214-231 (2012)
  3. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ. Nature 571 211-218 (2019)
  4. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Nature 510 278-282 (2014)
  5. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T. Nature 552 126-131 (2017)
  6. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. Cancer Cell 24 777-790 (2013)
  7. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender JD, Chun HB, Tough DF, Prinjha RK, Benner C, Glass CK. Mol Cell 51 310-325 (2013)
  8. What are super-enhancers? Pott S, Lieb JD. Nat Genet 47 8-12 (2015)
  9. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Nat Biotechnol 33 661-667 (2015)
  10. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K. Cancer Discov 3 308-323 (2013)
  11. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Ogilvie DJ, Somervaille TC. Cancer Cell 21 473-487 (2012)
  12. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K. Cell Rep 17 1193-1205 (2016)
  13. BET inhibitor resistance emerges from leukaemia stem cells. Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA. Nature 525 538-542 (2015)
  14. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, Minder JL, Mercan F, Wang E, Eckersley-Maslin MA, Campbell AE, Kawaoka S, Shareef S, Zhu Z, Kendall J, Muhar M, Haslinger C, Yu M, Roeder RG, Wigler MH, Blobel GA, Zuber J, Spector DL, Young RA, Vakoc CR. Genes Dev 27 2648-2662 (2013)
  15. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, Dias JML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS, Rausch O, Tzelepis K, Kouzarides T. Nature 593 597-601 (2021)
  16. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, Rusinova E, Zhang G, Wang C, Zhu H, Yao J, Zeng YX, Evers BM, Zhou MM, Zhou BP. Cancer Cell 25 210-225 (2014)
  17. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J. Nature 525 543-547 (2015)
  18. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. Cell 158 989-999 (2014)
  19. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. Blood 120 2843-2852 (2012)
  20. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. Cell 163 174-186 (2015)
  21. Small-molecule inhibition of BRDT for male contraception. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE. Cell 150 673-684 (2012)
  22. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein BE. Nat Genet 46 364-370 (2014)
  23. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Proc Natl Acad Sci U S A 109 19408-19413 (2012)
  24. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ, Singer DS. Proc Natl Acad Sci U S A 109 6927-6932 (2012)
  25. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. Mol Cell 58 1028-1039 (2015)
  26. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Cancer Cell 27 589-602 (2015)
  27. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM. Mol Cell 49 843-857 (2013)
  28. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Müller S, Brennan PE, Knapp S, Filippakopoulos P. Proc Natl Acad Sci U S A 110 19754-19759 (2013)
  29. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. Cancer Cell 25 652-665 (2014)
  30. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Kanno T, Kanno Y, LeRoy G, Campos E, Sun HW, Brooks SR, Vahedi G, Heightman TD, Garcia BA, Reinberg D, Siebenlist U, O'Shea JJ, Ozato K. Nat Struct Mol Biol 21 1047-1057 (2014)
  31. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J. Clin Cancer Res 19 1748-1759 (2013)
  32. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, Hess JL, Atadja P, Lei M, Qin ZS, Malek S, Wang S, Dou Y. Mol Cell 53 247-261 (2014)
  33. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Li Z, Guo J, Wu Y, Zhou Q. Nucleic Acids Res 41 277-287 (2013)
  34. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M. Cancer Cell 31 635-652.e6 (2017)
  35. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Nat Chem Biol 10 305-312 (2014)
  36. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL. Cell Rep 9 1841-1855 (2014)
  37. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M. Cell Cycle 12 452-462 (2013)
  38. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Cancer Cell 33 512-526.e8 (2018)
  39. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW. Cell Rep 18 2162-2174 (2017)
  40. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Proc Natl Acad Sci U S A 109 5028-5033 (2012)
  41. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song Y, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J. Cancer Discov 7 884-899 (2017)
  42. SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Muhar M, Ebert A, Neumann T, Umkehrer C, Jude J, Wieshofer C, Rescheneder P, Lipp JJ, Herzog VA, Reichholf B, Cisneros DA, Hoffmann T, Schlapansky MF, Bhat P, von Haeseler A, Köcher T, Obenauf AC, Popow J, Ameres SL, Zuber J. Science 360 800-805 (2018)
  43. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, Lam EYN, Chung CW, Bamborough P, Petretich M, Urh M, Atkinson SJ, Bassil AK, Roberts EJ, Vassiliadis D, Burr ML, Preston AGS, Wellaway C, Werner T, Gray JR, Michon AM, Gobbetti T, Kumar V, Soden PE, Haynes A, Vappiani J, Tough DF, Taylor S, Dawson SJ, Bantscheff M, Lindon M, Drewes G, Demont EH, Daniels DL, Grandi P, Prinjha RK, Dawson MA. Science 368 387-394 (2020)
  44. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. Vidler LR, Brown N, Knapp S, Hoelder S. J Med Chem 55 7346-7359 (2012)
  45. BET bromodomain inhibition suppresses TH17-mediated pathology. Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM. J Exp Med 210 2181-2190 (2013)
  46. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. Cancer Cell 33 401-416.e8 (2018)
  47. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Nat Med 23 1055-1062 (2017)
  48. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, Parsons R. Cancer Cell 27 837-851 (2015)
  49. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews JM, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, Chen J. Cancer Cell 22 524-535 (2012)
  50. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Müller S, Schwaller J, Stankovic T, Knapp S. Cancer Res 73 3336-3346 (2013)
  51. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function. Sakamaki JI, Wilkinson S, Hahn M, Tasdemir N, O'Prey J, Clark W, Hedley A, Nixon C, Long JS, New M, Van Acker T, Tooze SA, Lowe SW, Dikic I, Ryan KM. Mol Cell 66 517-532.e9 (2017)
  52. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Chen C, Liu Y, Lu C, Cross JR, Morris JP, Shroff AS, Ward PS, Bradner JE, Thompson C, Lowe SW. Genes Dev 27 1974-1985 (2013)
  53. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Di Micco R, Fontanals-Cirera B, Low V, Ntziachristos P, Yuen SK, Lovell CD, Dolgalev I, Yonekubo Y, Zhang G, Rusinova E, Gerona-Navarro G, Cañamero M, Ohlmeyer M, Aifantis I, Zhou MM, Tsirigos A, Hernando E. Cell Rep 9 234-247 (2014)
  54. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J, Chuang PY, Ohlmeyer M, He JC, Zhou MM. J Biol Chem 287 28840-28851 (2012)
  55. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JC. J Clin Invest 123 3876-3888 (2013)
  56. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C. Oncotarget 6 17698-17712 (2015)
  57. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Hammitzsch A, Tallant C, Fedorov O, O'Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, Vecellio M, Wells C, Wordsworth P, Müller S, Knapp S, Bowness P. Proc Natl Acad Sci U S A 112 10768-10773 (2015)
  58. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M, Jubierre L, Zhang W, Darvishian F, Ohlmeyer M, Osman I, Zhou MM, Hernando E. Cancer Res 73 6264-6276 (2013)
  59. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, Joseph JK, Wang X, Loh YE, Erb MA, Souza AL, Bradner JE, Shen L, Li W, Li H, Allis CD, Armstrong SA, Shi X. Nature 543 265-269 (2017)
  60. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. Genes Dev 28 1800-1814 (2014)
  61. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Bandukwala HS, Gagnon J, Togher S, Greenbaum JA, Lamperti ED, Parr NJ, Molesworth AM, Smithers N, Lee K, Witherington J, Tough DF, Prinjha RK, Peters B, Rao A. Proc Natl Acad Sci U S A 109 14532-14537 (2012)
  62. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S, Marshall S, Florens L, Washburn MP, Shilatifard A. Mol Cell Biol 32 2608-2617 (2012)
  63. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA. Proc Natl Acad Sci U S A 111 E2721-30 (2014)
  64. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM. Proc Natl Acad Sci U S A 111 11365-11370 (2014)
  65. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, Olzscha H, Monteiro O, Martin S, Philpott M, Tumber A, Filippakopoulos P, Yapp C, Wells C, Che KH, Bannister A, Robson S, Kumar U, Parr N, Lee K, Lugo D, Jeffrey P, Taylor S, Vecellio ML, Bountra C, Brennan PE, O'Mahony A, Velichko S, Müller S, Hay D, Daniels DL, Urh M, La Thangue NB, Kouzarides T, Prinjha R, Schwaller J, Knapp S. Cancer Res 75 5106-5119 (2015)
  66. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, Drewes G, Lee K, Bullinger L, Prinjha RK, Kouzarides T, Vassiliou GS, Huntly BJ. Leukemia 28 311-320 (2014)
  67. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, Picaud S, Philpott M, Monteiro OP, Rogers CM, Conway SJ, Rooney TP, Tumber A, Yapp C, Filippakopoulos P, Bunnage ME, Müller S, Knapp S, Schofield CJ, Brennan PE. J Am Chem Soc 136 9308-9319 (2014)
  68. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S. Blood 124 13-23 (2014)
  69. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, Kennedy-Wilson KM, Sanchez LV, Gosmini RL, Parr N, McHugh CF, Dhanak D, Prinjha RK, Auger KR, Tummino PJ. PLoS One 8 e72967 (2013)
  70. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L. Sci Transl Med 9 eaal1645 (2017)
  71. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A. Blood 123 697-705 (2014)
  72. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW. Cell Res 24 809-819 (2014)
  73. BRD4 is a novel therapeutic target for liver fibrosis. Ding N, Hah N, Yu RT, Sherman MH, Benner C, Leblanc M, He M, Liddle C, Downes M, Evans RM. Proc Natl Acad Sci U S A 112 15713-15718 (2015)
  74. Genome-wide localization of small molecules. Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Lovén J, Sigova AA, Smith WB, Lee TI, Bradner JE, Young RA. Nat Biotechnol 32 92-96 (2014)
  75. Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis. Lee JE, Park YK, Park S, Jang Y, Waring N, Dey A, Ozato K, Lai B, Peng W, Ge K. Nat Commun 8 2217 (2017)
  76. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, Ralph MJ, Sciammetta N, Trzupek JD. J Med Chem 55 9831-9837 (2012)
  77. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Alekseyenko AA, Walsh EM, Wang X, Grayson AR, Hsi PT, Kharchenko PV, Kuroda MI, French CA. Genes Dev 29 1507-1523 (2015)
  78. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, Livingston DM. Proc Natl Acad Sci U S A 112 232-237 (2015)
  79. BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. Bhagwat AS, Roe JS, Mok BYL, Hohmann AF, Shi J, Vakoc CR. Cell Rep 15 519-530 (2016)
  80. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. Mol Cancer Res 14 324-331 (2016)
  81. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN. Mol Cancer Ther 13 2315-2327 (2014)
  82. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, de Bruijn MF, Milne TA. Cell Rep 3 116-127 (2013)
  83. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, MacNevin CJ, Norris JL, Sagum CA, Tempel W, Marcon E, Guo H, Gao C, Huang XP, Duan S, Emili A, Greenblatt JF, Kireev DB, Jin J, Janzen WP, Brown PJ, Bedford MT, Arrowsmith CH, Frye SV. Nat Chem Biol 9 184-191 (2013)
  84. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, Lee SC, Danet-Desnoyers G, Trotman W, Kandarpa M, Cotton A, Abdel-Wahab O, Lei H, Dou Y, Guzman M, Peterson L, Gruber T, Choi S, Sun D, Ren P, Li LS, Liu Y, Burrows F, Maillard I, Cierpicki T, Grembecka J. J Clin Invest 130 981-997 (2020)
  85. Biological plasticity rescues target activity in CRISPR knock outs. Smits AH, Ziebell F, Joberty G, Zinn N, Mueller WF, Clauder-Münster S, Eberhard D, Fälth Savitski M, Grandi P, Jakob P, Michon AM, Sun H, Tessmer K, Bürckstümmer T, Bantscheff M, Steinmetz LM, Drewes G, Huber W. Nat Methods 16 1087-1093 (2019)
  86. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, Chung CW, Dittmann A, Drewes G, Drewry DH, Gordon L, Grandi P, Leveridge M, Lindon M, Michon AM, Molnar J, Robson SC, Tomkinson NC, Kouzarides T, Prinjha RK, Humphreys PG. J Med Chem 59 1425-1439 (2016)
  87. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. Blood 130 48-58 (2017)
  88. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. Shen C, Ipsaro JJ, Shi J, Milazzo JP, Wang E, Roe JS, Suzuki Y, Pappin DJ, Joshua-Tor L, Vakoc CR. Mol Cell 60 847-859 (2015)
  89. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Cancer Res 77 2476-2487 (2017)
  90. Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG, Lenhard B, Chan LC, So CW. Cancer Cell 29 32-48 (2016)
  91. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O. Oncotarget 4 2419-2429 (2013)
  92. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. Palanichamy JK, Tran TM, Howard JM, Contreras JR, Fernando TR, Sterne-Weiler T, Katzman S, Toloue M, Yan W, Basso G, Pigazzi M, Sanford JR, Rao DS. J Clin Invest 126 1495-1511 (2016)
  93. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. Jung M, Philpott M, Müller S, Schulze J, Badock V, Eberspächer U, Moosmayer D, Bader B, Schmees N, Fernández-Montalván A, Haendler B. J Biol Chem 289 9304-9319 (2014)
  94. BET bromodomain proteins are required for glioblastoma cell proliferation. Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG. Epigenetics 9 611-620 (2014)
  95. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Rodriguez-Paredes M, Martinez de Paz A, Simó-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, Vázquez-Cedeira M, Lazo PA, Carneiro F, Moura CS, Vieira J, Teixeira MR, Esteller M. Oncogene 33 2807-2813 (2014)
  96. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, Dhar A, Karpinich N, Tian L, Tyler DS, MacPherson L, Shi J, Pinnawala N, Yew Fong C, Papenfuss AT, Grimmond SM, Dawson SJ, Allan RS, Kruger RG, Vakoc CR, Goode DL, Naik SH, Gilan O, Lam EYN, Marine JC, Prinjha RK, Dawson MA. Nat Commun 10 2723 (2019)
  97. RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey KM, Komives EA, Lauberth SM. Nat Struct Mol Biol 25 687-697 (2018)
  98. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. Chan KH, Zengerle M, Testa A, Ciulli A. J Med Chem 61 504-513 (2018)
  99. A quantitative atlas of histone modification signatures from human cancer cells. Leroy G, Dimaggio PA, Chan EY, Zee BM, Blanco MA, Bryant B, Flaniken IZ, Liu S, Kang Y, Trojer P, Garcia BA. Epigenetics Chromatin 6 20 (2013)
  100. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh DN, Xu F, Hu J, Xiang W, Huang L, Li S, Wen B, Sun D, Wang S. J Med Chem 61 6685-6704 (2018)
  101. Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis. Savitski MM, Zinn N, Faelth-Savitski M, Poeckel D, Gade S, Becher I, Muelbaier M, Wagner AJ, Strohmer K, Werner T, Melchert S, Petretich M, Rutkowska A, Vappiani J, Franken H, Steidel M, Sweetman GM, Gilan O, Lam EYN, Dawson MA, Prinjha RK, Grandi P, Bergamini G, Bantscheff M. Cell 173 260-274.e25 (2018)
  102. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Baker EK, Taylor S, Gupte A, Sharp PP, Walia M, Walsh NC, Zannettino AC, Chalk AM, Burns CJ, Walkley CR. Sci Rep 5 10120 (2015)
  103. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Baud MGJ, Lin-Shiao E, Cardote T, Tallant C, Pschibul A, Chan KH, Zengerle M, Garcia JR, Kwan TT, Ferguson FM, Ciulli A. Science 346 638-641 (2014)
  104. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, Leblanc M, Collisson EA, Asara JM, Kimmelman AC, Downes M, Evans RM. Proc Natl Acad Sci U S A 114 1129-1134 (2017)
  105. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. Cell Rep 13 2715-2727 (2015)
  106. BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling. Andrieu G, Tran AH, Strissel KJ, Denis GV. Cancer Res 76 6555-6567 (2016)
  107. How chemoproteomics can enable drug discovery and development. Moellering RE, Cravatt BF. Chem Biol 19 11-22 (2012)
  108. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Gopalakrishnan R, Matta H, Tolani B, Triche T, Chaudhary PM. Oncogene 35 1797-1810 (2016)
  109. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. Gacias M, Gerona-Navarro G, Plotnikov AN, Zhang G, Zeng L, Kaur J, Moy G, Rusinova E, Rodriguez Y, Matikainen B, Vincek A, Joshua J, Casaccia P, Zhou MM. Chem Biol 21 841-854 (2014)
  110. The role of bromodomain proteins in regulating gene expression. Josling GA, Selvarajah SA, Petter M, Duffy MF. Genes (Basel) 3 320-343 (2012)
  111. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR, Bartom ET, Gilmore JM, Florens L, Washburn MP, Sullivan KD, Espinosa JM, Cannova J, Zhang J, Smith ER, Crispino JD, Shilatifard A. Cell 168 59-72.e13 (2017)
  112. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains. Lambert JP, Picaud S, Fujisawa T, Hou H, Savitsky P, Uusküla-Reimand L, Gupta GD, Abdouni H, Lin ZY, Tucholska M, Knight JDR, Gonzalez-Badillo B, St-Denis N, Newman JA, Stucki M, Pelletier L, Bandeira N, Wilson MD, Filippakopoulos P, Gingras AC. Mol Cell 73 621-638.e17 (2019)
  113. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. Long J, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Wahlestedt C, Capobianco A, Bai F, Pei XH, Ayad NG, Robbins DJ. J Biol Chem 289 35494-35502 (2014)
  114. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Hussong M, Börno ST, Kerick M, Wunderlich A, Franz A, Sültmann H, Timmermann B, Lehrach H, Hirsch-Kauffmann M, Schweiger MR. Cell Death Dis 5 e1195 (2014)
  115. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. Martin MP, Olesen SH, Georg GI, Schönbrunn E. ACS Chem Biol 8 2360-2365 (2013)
  116. The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries. Hsu SC, Gilgenast TG, Bartman CR, Edwards CR, Stonestrom AJ, Huang P, Emerson DJ, Evans P, Werner MT, Keller CA, Giardine B, Hardison RC, Raj A, Phillips-Cremins JE, Blobel GA. Mol Cell 66 102-116.e7 (2017)
  117. The RNA Pol II elongation factor Ell3 marks enhancers in ES cells and primes future gene activation. Lin C, Garruss AS, Luo Z, Guo F, Shilatifard A. Cell 152 144-156 (2013)
  118. BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. Richart L, Carrillo-de Santa Pau E, Río-Machín A, de Andrés MP, Cigudosa JC, Lobo VJS, Real FX. Nat Commun 7 10153 (2016)
  119. Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation. Cheung KL, Zhang F, Jaganathan A, Sharma R, Zhang Q, Konuma T, Shen T, Lee JY, Ren C, Chen CH, Lu G, Olson MR, Zhang W, Kaplan MH, Littman DR, Walsh MJ, Xiong H, Zeng L, Zhou MM. Mol Cell 65 1068-1080.e5 (2017)
  120. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Alekseyenko AA, Walsh EM, Zee BM, Pakozdi T, Hsi P, Lemieux ME, Dal Cin P, Ince TA, Kharchenko PV, Kuroda MI, French CA. Proc Natl Acad Sci U S A 114 E4184-E4192 (2017)
  121. How I treat mixed-phenotype acute leukemia. Wolach O, Stone RM. Blood 125 2477-2485 (2015)
  122. A gene-environment-induced epigenetic program initiates tumorigenesis. Alonso-Curbelo D, Ho YJ, Burdziak C, Maag JLV, Morris JP, Chandwani R, Chen HA, Tsanov KM, Barriga FM, Luan W, Tasdemir N, Livshits G, Azizi E, Chun J, Wilkinson JE, Mazutis L, Leach SD, Koche R, Pe'er D, Lowe SW. Nature 590 642-648 (2021)
  123. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC, Ghisi M, Smil D, Carpenter C, Brown P, Garton N, Blewitt ME, Bannister AJ, Kouzarides T, Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA. Nat Struct Mol Biol 23 673-681 (2016)
  124. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Stewart HJ, Horne GA, Bastow S, Chevassut TJ. Cancer Med 2 826-835 (2013)
  125. Challenges for assessing replicability in preclinical cancer biology. Errington TM, Denis A, Perfito N, Iorns E, Nosek BA. Elife 10 e67995 (2021)
  126. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, Shaham M, Rivlin A, Omer I, Zinger A, Elias S, Winter E, Erdman PE, Sullivan RW, Fung L, Mercurio F, Li D, Vacca J, Kaushansky N, Shlush L, Oren M, Levine R, Pikarsky E, Snir-Alkalay I, Ben-Neriah Y. Cell 175 171-185.e25 (2018)
  127. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, Mochizuki-Kashio M, Harada H, Shimoda K, Iwama A. J Exp Med 213 1459-1477 (2016)
  128. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ, Ebine K, Munshi HG. Mol Cancer Ther 13 1907-1917 (2014)
  129. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. Zhang G, Plotnikov AN, Rusinova E, Shen T, Morohashi K, Joshua J, Zeng L, Mujtaba S, Ohlmeyer M, Zhou MM. J Med Chem 56 9251-9264 (2013)
  130. The Bromodomain: A New Target in Emerging Epigenetic Medicine. Smith SG, Zhou MM. ACS Chem Biol 11 598-608 (2016)
  131. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Kumar K, Raza SS, Knab LM, Chow CR, Kwok B, Bentrem DJ, Popovic R, Ebine K, Licht JD, Munshi HG. Sci Rep 5 9489 (2015)
  132. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L, Myeroff L, Kalady MF, Willis J, Bradner JE, Keri RA, Berger NA, Pruett-Miller SM, Markowitz SD, Scacheri PC. Nat Commun 8 14400 (2017)
  133. Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Park-Min KH, Lim E, Lee MJ, Park SH, Giannopoulou E, Yarilina A, van der Meulen M, Zhao B, Smithers N, Witherington J, Lee K, Tak PP, Prinjha RK, Ivashkiv LB. Nat Commun 5 5418 (2014)
  134. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, Sugiyama T, Katai H, Noshiro H, Ushijima T. Gastric Cancer 18 65-76 (2015)
  135. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Oncogene 33 2928-2937 (2014)
  136. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy. Liang K, Smith ER, Aoi Y, Stoltz KL, Katagi H, Woodfin AR, Rendleman EJ, Marshall SA, Murray DC, Wang L, Ozark PA, Mishra RK, Hashizume R, Schiltz GE, Shilatifard A. Cell 175 766-779.e17 (2018)
  137. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG. Proc Natl Acad Sci U S A 114 E1072-E1080 (2017)
  138. Functions of BET proteins in erythroid gene expression. Stonestrom AJ, Hsu SC, Jahn KS, Huang P, Keller CA, Giardine BM, Kadauke S, Campbell AE, Evans P, Hardison RC, Blobel GA. Blood 125 2825-2834 (2015)
  139. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, Filipescu D, Valle-Garcia D, Darvishian F, Roe JS, Davies MA, Vakoc CR, Hernando E, Bernstein E. Mol Cell 68 731-744.e9 (2017)
  140. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma. Tsang FH, Law CT, Tang TC, Cheng CL, Chin DW, Tam WV, Wei L, Wong CC, Ng IO, Wong CM. Hepatology 69 2502-2517 (2019)
  141. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Tyler DS, Vappiani J, Cañeque T, Lam EYN, Ward A, Gilan O, Chan YC, Hienzsch A, Rutkowska A, Werner T, Wagner AJ, Lugo D, Gregory R, Ramirez Molina C, Garton N, Wellaway CR, Jackson S, MacPherson L, Figueiredo M, Stolzenburg S, Bell CC, House C, Dawson SJ, Hawkins ED, Drewes G, Prinjha RK, Rodriguez R, Grandi P, Dawson MA. Science 356 1397-1401 (2017)
  142. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Blood 126 1565-1574 (2015)
  143. Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity. Kim JJ, Lee SY, Gong F, Battenhouse AM, Boutz DR, Bashyal A, Refvik ST, Chiang CM, Xhemalce B, Paull TT, Brodbelt JS, Marcotte EM, Miller KM. Genes Dev 33 1751-1774 (2019)
  144. Super-enhancers in transcriptional regulation and genome organization. Wang X, Cairns MJ, Yan J. Nucleic Acids Res 47 11481-11496 (2019)
  145. Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication. Wang X, Li J, Schowalter RM, Jiao J, Buck CB, You J. PLoS Pathog 8 e1003021 (2012)
  146. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Xu L, Chen Y, Mayakonda A, Koh L, Chong YK, Buckley DL, Sandanaraj E, Lim SW, Lin RY, Ke XY, Huang ML, Chen J, Sun W, Wang LZ, Goh BC, Dinh HQ, Kappei D, Winter GE, Ding LW, Ang BT, Berman BP, Bradner JE, Tang C, Koeffler HP. Proc Natl Acad Sci U S A 115 E5086-E5095 (2018)
  147. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Shao Q, Kannan A, Lin Z, Stack BC, Suen JY, Gao L. Cancer Res 74 7090-7102 (2014)
  148. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS, Huntly BJP. J Exp Med 216 966-981 (2019)
  149. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, Tummino PJ, Rizos H, Hersey P. Pigment Cell Melanoma Res 27 1126-1137 (2014)
  150. shRNA screening identifies JMJD1C as being required for leukemia maintenance. Sroczynska P, Cruickshank VA, Bukowski JP, Miyagi S, Bagger FO, Walfridsson J, Schuster MB, Porse B, Helin K. Blood 123 1870-1882 (2014)
  151. BET inhibition disrupts transcription but retains enhancer-promoter contact. Crump NT, Ballabio E, Godfrey L, Thorne R, Repapi E, Kerry J, Tapia M, Hua P, Lagerholm C, Filippakopoulos P, Davies JOJ, Milne TA. Nat Commun 12 223 (2021)
  152. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. Leukemia 31 678-687 (2017)
  153. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R. Cancer Discov 8 458-477 (2018)
  154. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Dafflon C, Craig VJ, Méreau H, Gräsel J, Schacher Engstler B, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J, Bornhauser B, Bourquin JP, Proske A, Stork-Fux C, Murakami M, Sellers WR, Hofmann F, Schwaller J, Tiedt R. Leukemia 31 1269-1277 (2017)
  155. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V, Kohlhof H, Hessmann E, Johnsen SA. Nucleic Acids Res 45 6334-6349 (2017)
  156. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ, Zhuang G. Theranostics 6 219-230 (2016)
  157. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. Vidler LR, Filippakopoulos P, Fedorov O, Picaud S, Martin S, Tomsett M, Woodward H, Brown N, Knapp S, Hoelder S. J Med Chem 56 8073-8088 (2013)
  158. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR. Blood 119 5838-5849 (2012)
  159. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA, Roeder RG. Genes Dev 29 2123-2139 (2015)
  160. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Prange KHM, Mandoli A, Kuznetsova T, Wang SY, Sotoca AM, Marneth AE, van der Reijden BA, Stunnenberg HG, Martens JHA. Oncogene 36 3346-3356 (2017)
  161. Potent and selective bivalent inhibitors of BET bromodomains. Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, Bradbury RH, Callis R, Clark E, Dale I, Daniels DL, Dulak A, Flavell L, Holdgate G, Jowitt TA, Kikhney A, McAlister M, Méndez J, Ogg D, Patel J, Petteruti P, Robb GR, Robers MB, Saif S, Stratton N, Svergun DI, Wang W, Whittaker D, Wilson DM, Yao Y. Nat Chem Biol 12 1097-1104 (2016)
  162. An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. Matkar S, Sharma P, Gao S, Gurung B, Katona BW, Liao J, Muhammad AB, Kong XC, Wang L, Jin G, Dang CV, Hua X. Cancer Cell 28 472-485 (2015)
  163. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A, Oldreive C, Wei W, Stewart G, Longman J, Smith E, Kearns P, Knapp S, Stankovic T. Blood Cancer J 3 e126 (2013)
  164. LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. Ji X, Lu H, Zhou Q, Luo K. Elife 3 e02907 (2014)
  165. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW. Cell Stem Cell 15 775-790 (2014)
  166. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Hu Y, Zhou J, Ye F, Xiong H, Peng L, Zheng Z, Xu F, Cui M, Wei C, Wang X, Wang Z, Zhu H, Lee P, Zhou M, Jiang B, Zhang DY. Int J Mol Sci 16 1928-1948 (2015)
  167. Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. Bennett J, Fedorov O, Tallant C, Monteiro O, Meier J, Gamble V, Savitsky P, Nunez-Alonso GA, Haendler B, Rogers C, Brennan PE, Müller S, Knapp S. J Med Chem 59 1642-1647 (2016)
  168. Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Korkut A, Wang W, Demir E, Aksoy BA, Jing X, Molinelli EJ, Babur Ö, Bemis DL, Onur Sumer S, Solit DB, Pratilas CA, Sander C. Elife 4 (2015)
  169. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. Mol Cancer Ther 15 1018-1028 (2016)
  170. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Patel AJ, Liao CP, Chen Z, Liu C, Wang Y, Le LQ. Cell Rep 6 81-92 (2014)
  171. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Conery AR, Centore RC, Neiss A, Keller PJ, Joshi S, Spillane KL, Sandy P, Hatton C, Pardo E, Zawadzke L, Bommi-Reddy A, Gascoigne KE, Bryant BM, Mertz JA, Sims RJ. Elife 5 e10483 (2016)
  172. Epe1 recruits BET family bromodomain protein Bdf2 to establish heterochromatin boundaries. Wang J, Tadeo X, Hou H, Tu PG, Thompson J, Yates JR, Jia S. Genes Dev 27 1886-1902 (2013)
  173. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells. Fu W, Farache J, Clardy SM, Hattori K, Mander P, Lee K, Rioja I, Weissleder R, Prinjha RK, Benoist C, Mathis D. Elife 3 e04631 (2014)
  174. The double PHD finger domain of MOZ/MYST3 induces α-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification. Dreveny I, Deeves SE, Fulton J, Yue B, Messmer M, Bhattacharya A, Collins HM, Heery DM. Nucleic Acids Res 42 822-835 (2014)
  175. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell. Deeney JT, Belkina AC, Shirihai OS, Corkey BE, Denis GV. PLoS One 11 e0151329 (2016)
  176. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. Kaushik S, Liu F, Veazey KJ, Gao G, Das P, Neves LF, Lin K, Zhong Y, Lu Y, Giuliani V, Bedford MT, Nimer SD, Santos MA. Leukemia 32 499-509 (2018)
  177. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE, Frank DA. Mol Cancer Ther 13 1194-1205 (2014)
  178. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Lucas X, Wohlwend D, Hügle M, Schmidtkunz K, Gerhardt S, Schüle R, Jung M, Einsle O, Günther S. Angew Chem Int Ed Engl 52 14055-14059 (2013)
  179. A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Xu Y, Milazzo JP, Somerville TDD, Tarumoto Y, Huang YH, Ostrander EL, Wilkinson JE, Challen GA, Vakoc CR. Cancer Cell 33 13-28.e8 (2018)
  180. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Wyspiańska BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto FJ, Robson S, Rioja I, Li J, Wiese M, Cannizzaro E, Dawson MA, Huntly B, Prinjha RK, Green AR, Gottgens B, Kouzarides T. Leukemia 28 88-97 (2014)
  181. Biased multicomponent reactions to develop novel bromodomain inhibitors. McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. J Med Chem 57 9019-9027 (2014)
  182. ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T. Cancer Cell 31 452-465 (2017)
  183. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia. Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C, Conte N, Andrews RM, Pacharne S, Tzelepis K, Vijayabaskar MS, Green P, Rad R, Arends M, Wright P, Yusa K, Bradley A, Varela I, Vassiliou GS. Blood 130 1911-1922 (2017)
  184. BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes. Chan CH, Fang C, Yarilina A, Prinjha RK, Qiao Y, Ivashkiv LB. Eur J Immunol 45 287-297 (2015)
  185. BRD4 short isoform interacts with RRP1B, SIPA1 and components of the LINC complex at the inner face of the nuclear membrane. Alsarraj J, Faraji F, Geiger TR, Mattaini KR, Williams M, Wu J, Ha NH, Merlino T, Walker RC, Bosley AD, Xiao Z, Andresson T, Esposito D, Smithers N, Lugo D, Prinjha R, Day A, Crawford NP, Ozato K, Gardner K, Hunter KW. PLoS One 8 e80746 (2013)
  186. Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. Gehling VS, Hewitt MC, Vaswani RG, Leblanc Y, Côté A, Nasveschuk CG, Taylor AM, Harmange JC, Audia JE, Pardo E, Joshi S, Sandy P, Mertz JA, Sims RJ, Bergeron L, Bryant BM, Bellon S, Poy F, Jayaram H, Sankaranarayanan R, Yellapantula S, Bangalore Srinivasamurthy N, Birudukota S, Albrecht BK. ACS Med Chem Lett 4 835-840 (2013)
  187. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, Hall MD, Guha R, Davis MI, Menard M, Nasholm N, Weiss WA, Qi J, Beroukhim R, Piccioni F, Johannessen C, Stegmaier K. Cancer Cell 34 922-938.e7 (2018)
  188. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Lu P, Qu X, Shen Y, Jiang Z, Wang P, Zeng H, Ji H, Deng J, Yang X, Li X, Lu H, Zhu H. Sci Rep 6 24100 (2016)
  189. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H, Hersey P. J Invest Dermatol 134 2795-2805 (2014)
  190. High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Gier RA, Budinich KA, Evitt NH, Cao Z, Freilich ES, Chen Q, Qi J, Lan Y, Kohli RM, Shi J. Nat Commun 11 3455 (2020)
  191. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Ansari KI, Kasiri S, Mandal SS. Oncogene 32 3359-3370 (2013)
  192. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Vijayakrishnan J, Qian M, Studd JB, Yang W, Kinnersley B, Law PJ, Broderick P, Raetz EA, Allan J, Pui CH, Vora A, Evans WE, Moorman A, Yeoh A, Yang W, Li C, Bartram CR, Mullighan CG, Zimmerman M, Hunger SP, Schrappe M, Relling MV, Stanulla M, Loh ML, Houlston RS, Yang JJ. Nat Commun 10 5348 (2019)
  193. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD. Blood 129 2882-2895 (2017)
  194. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Siu KT, Ramachandran J, Yee AJ, Eda H, Santo L, Panaroni C, Mertz JA, Sims Iii RJ, Cooper MR, Raje N. Leukemia 31 1760-1769 (2017)
  195. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. Horne GA, Stewart HJ, Dickson J, Knapp S, Ramsahoye B, Chevassut T. Stem Cells Dev 24 879-891 (2015)
  196. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS. Nat Commun 9 5378 (2018)
  197. Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. Fernandez P, Scaffidi P, Markert E, Lee JH, Rane S, Misteli T. Cell Rep 9 248-260 (2014)
  198. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC. Ba M, Long H, Yan Z, Wang S, Wu Y, Tu Y, Gong Y, Cui S. J Cell Biochem 119 973-982 (2018)
  199. Resetting cancer stem cell regulatory nodes upon MYC inhibition. Galardi S, Savino M, Scagnoli F, Pellegatta S, Pisati F, Zambelli F, Illi B, Annibali D, Beji S, Orecchini E, Alberelli MA, Apicella C, Fontanella RA, Michienzi A, Finocchiaro G, Farace MG, Pavesi G, Ciafrè SA, Nasi S. EMBO Rep 17 1872-1889 (2016)
  200. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Yamamoto K, Tateishi K, Kudo Y, Hoshikawa M, Tanaka M, Nakatsuka T, Fujiwara H, Miyabayashi K, Takahashi R, Tanaka Y, Ijichi H, Nakai Y, Isayama H, Morishita Y, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M, Koike K. Oncotarget 7 61469-61484 (2016)
  201. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH. Oncotarget 7 1451-1463 (2016)
  202. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJ. Oncogene 35 279-289 (2016)
  203. Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice. Sullivan JM, Badimon A, Schaefer U, Ayata P, Gray J, Chung CW, von Schimmelmann M, Zhang F, Garton N, Smithers N, Lewis H, Tarakhovsky A, Prinjha RK, Schaefer A. J Exp Med 212 1771-1781 (2015)
  204. High level of BRD4 promotes non-small cell lung cancer progression. Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ, Ding JY. Oncotarget 7 9491-9500 (2016)
  205. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. Suarez-Alvarez B, Morgado-Pascual JL, Rayego-Mateos S, Rodriguez RM, Rodrigues-Diez R, Cannata-Ortiz P, Sanz AB, Egido J, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M. J Am Soc Nephrol 28 504-519 (2017)
  206. Stimulation of β-catenin and colon cancer cell growth by the KDM4B histone demethylase. Berry WL, Kim TD, Janknecht R. Int J Oncol 44 1341-1348 (2014)
  207. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Blood Cancer J 9 4 (2019)
  208. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. Clin Cancer Res 26 1247-1257 (2020)
  209. High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Zhao Y, Liu Q, Acharya P, Stengel KR, Sheng Q, Zhou X, Kwak H, Fischer MA, Bradner JE, Strickland SA, Mohan SR, Savona MR, Venters BJ, Zhou MM, Lis JT, Hiebert SW. Cell Rep 16 2003-2016 (2016)
  210. Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140. Mehta S, Cronkite DA, Basavappa M, Saunders TL, Adiliaghdam F, Amatullah H, Morrison SA, Pagan JD, Anthony RM, Tonnerre P, Lauer GM, Lee JC, Digumarthi S, Pantano L, Ho Sui SJ, Ji F, Sadreyev R, Zhou C, Mullen AC, Kumar V, Li Y, Wijmenga C, Xavier RJ, Means TK, Jeffrey KL. Sci Immunol 2 eaag3160 (2017)
  211. The non-coding snRNA 7SK controls transcriptional termination, poising, and bidirectionality in embryonic stem cells. Castelo-Branco G, Amaral PP, Engström PG, Robson SC, Marques SC, Bertone P, Kouzarides T. Genome Biol 14 R98 (2013)
  212. A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction. Rooney TP, Filippakopoulos P, Fedorov O, Picaud S, Cortopassi WA, Hay DA, Martin S, Tumber A, Rogers CM, Philpott M, Wang M, Thompson AL, Heightman TD, Pryde DC, Cook A, Paton RS, Müller S, Knapp S, Brennan PE, Conway SJ. Angew Chem Int Ed Engl 53 6126-6130 (2014)
  213. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells. Ambrosini G, Sawle AD, Musi E, Schwartz GK. Oncotarget 6 33397-33409 (2015)
  214. lncRNA requirements for mouse acute myeloid leukemia and normal differentiation. Delás MJ, Sabin LR, Dolzhenko E, Knott SR, Munera Maravilla E, Jackson BT, Wild SA, Kovacevic T, Stork EM, Zhou M, Erard N, Lee E, Kelley DR, Roth M, Barbosa IA, Zuber J, Rinn JL, Smith AD, Hannon GJ. Elife 6 e25607 (2017)
  215. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K. Nat Commun 11 2350 (2020)
  216. BRD4 Prevents R-Loop Formation and Transcription-Replication Conflicts by Ensuring Efficient Transcription Elongation. Edwards DS, Maganti R, Tanksley JP, Luo J, Park JJH, Balkanska-Sinclair E, Ling J, Floyd SR. Cell Rep 32 108166 (2020)
  217. BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses. Wang J, Li GL, Ming SL, Wang CF, Shi LJ, Su BQ, Wu HT, Zeng L, Han YQ, Liu ZH, Jiang DW, Du YK, Li XD, Zhang GP, Yang GY, Chu BB. PLoS Pathog 16 e1008429 (2020)
  218. CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. Clifford RL, Patel JK, John AE, Tatler AL, Mazengarb L, Brightling CE, Knox AJ. Am J Physiol Lung Cell Mol Physiol 308 L962-72 (2015)
  219. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J. Eur J Med Chem 151 450-461 (2018)
  220. From oncogene to tumor suppressor: the dual role of Myc in leukemia. Uribesalgo I, Benitah SA, Di Croce L. Cell Cycle 11 1757-1764 (2012)
  221. MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Sdelci S, Rendeiro AF, Rathert P, You W, Lin JG, Ringler A, Hofstätter G, Moll HP, Gürtl B, Farlik M, Schick S, Klepsch F, Oldach M, Buphamalai P, Schischlik F, Májek P, Parapatics K, Schmidl C, Schuster M, Penz T, Buckley DL, Hudecz O, Imre R, Wang SY, Maric HM, Kralovics R, Bennett KL, Müller AC, Mechtler K, Menche J, Bradner JE, Winter GE, Klavins K, Casanova E, Bock C, Zuber J, Kubicek S. Nat Genet 51 990-998 (2019)
  222. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Kato F, Fiorentino FP, Alibés A, Perucho M, Sánchez-Céspedes M, Kohno T, Yokota J. Oncotarget 7 77378-77388 (2016)
  223. P-TEFb Activation by RBM7 Shapes a Pro-survival Transcriptional Response to Genotoxic Stress. Bugai A, Quaresma AJC, Friedel CC, Lenasi T, Düster R, Sibley CR, Fujinaga K, Kukanja P, Hennig T, Blasius M, Geyer M, Ule J, Dölken L, Barborič M. Mol Cell 74 254-267.e10 (2019)
  224. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition. Andrieu GP, Denis GV. Mol Cancer Res 16 580-586 (2018)
  225. The basal transcription machinery as a target for cancer therapy. Villicaña C, Cruz G, Zurita M. Cancer Cell Int 14 18 (2014)
  226. BET inhibition as a new strategy for the treatment of gastric cancer. Montenegro RC, Clark PG, Howarth A, Wan X, Ceroni A, Siejka P, Nunez-Alonso GA, Monteiro O, Rogers C, Gamble V, Burbano R, Brennan PE, Tallant C, Ebner D, Fedorov O, O'Neill E, Knapp S, Dixon D, Müller S. Oncotarget 7 43997-44012 (2016)
  227. Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. Barrow JJ, Balsa E, Verdeguer F, Tavares CD, Soustek MS, Hollingsworth LR, Jedrychowski M, Vogel R, Paulo JA, Smeitink J, Gygi SP, Doench J, Root DE, Puigserver P. Mol Cell 64 163-175 (2016)
  228. Comparative drug screening in NUT midline carcinoma. Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, Arndt GM, Charles AK, Cole CH, Kees UR. Br J Cancer 110 1189-1198 (2014)
  229. Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression. Hu X, Lu X, Liu R, Ai N, Cao Z, Li Y, Liu J, Yu B, Liu K, Wang H, Zhou C, Wang Y, Han A, Ding F, Chen R. J Biol Chem 289 23154-23167 (2014)
  230. LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. El Ashkar S, Schwaller J, Pieters T, Pieters T, Goossens S, Demeulemeester J, Demeulemeester J, Christ F, Van Belle S, Juge S, Boeckx N, Engelman A, Van Vlierberghe P, Debyser Z, De Rijck J. Blood 131 95-107 (2018)
  231. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms. Shi X, Mihaylova VT, Kuruvilla L, Chen F, Viviano S, Baldassarre M, Sperandio D, Martinez R, Yue P, Bates JG, Breckenridge DG, Schlessinger J, Turk BE, Calderwood DA. Proc Natl Acad Sci U S A 113 E4558-66 (2016)
  232. Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity. Finley LWS, Vardhana SA, Carey BW, Alonso-Curbelo D, Koche R, Chen Y, Wen D, King B, Radler MR, Rafii S, Lowe SW, Allis CD, Thompson CB. Nat Cell Biol 20 565-574 (2018)
  233. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. EMBO Mol Med 11 e9081 (2019)
  234. The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice. Benito E, Ramachandran B, Schroeder H, Schmidt G, Urbanke H, Burkhardt S, Capece V, Dean C, Fischer A. Transl Psychiatry 7 e1239 (2017)
  235. The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV. J Leukoc Biol 95 451-460 (2014)
  236. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. Wang R, Cao XJ, Kulej K, Liu W, Ma T, MacDonald M, Chiang CM, Garcia BA, You J. Proc Natl Acad Sci U S A 114 E5352-E5361 (2017)
  237. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. J Clin Invest 129 1878-1894 (2019)
  238. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Méreau H, De Rijck J, Cermáková K, Kutz A, Juge S, Demeulemeester J, Gijsbers R, Christ F, Debyser Z, Schwaller J. Leukemia 27 1245-1253 (2013)
  239. Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Baud'huin M, Lamoureux F, Jacques C, Rodriguez Calleja L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, Reilly GC, Bradner JE, Heymann D, Ory B. Bone 94 10-21 (2017)
  240. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W. Clin Cancer Res 18 6296-6305 (2012)
  241. BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Sun Y, Wang Y, Toubai T, Oravecz-Wilson K, Liu C, Mathewson N, Wu J, Rossi C, Cummings E, Wu D, Wang S, Reddy P. Blood 125 2724-2728 (2015)
  242. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. Zhang P, Dong Z, Cai J, Zhang C, Shen Z, Ke A, Gao D, Fan J, Shi G. Int J Immunopathol Pharmacol 28 36-44 (2015)
  243. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model. Sontakke P, Carretta M, Jaques J, Brouwers-Vos AZ, Lubbers-Aalders L, Yuan H, de Bruijn JD, Martens AC, Vellenga E, Groen RW, Schuringa JJ. Leukemia 30 2064-2073 (2016)
  244. BRD4-mediated repression of p53 is a target for combination therapy in AML. Latif AL, Newcombe A, Li S, Gilroy K, Robertson NA, Lei X, Stewart HJS, Cole J, Terradas MT, Rishi L, McGarry L, McKeeve C, Reid C, Clark W, Campos J, Kirschner K, Davis A, Lopez J, Sakamaki JI, Morton JP, Ryan KM, Tait SWG, Abraham SA, Holyoake T, Higgins B, Huang X, Blyth K, Copland M, Chevassut TJT, Keeshan K, Adams PD. Nat Commun 12 241 (2021)
  245. CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion. Kanjee U, Grüring C, Chaand M, Lin KM, Egan E, Manzo J, Jones PL, Yu T, Barker R, Weekes MP, Duraisingh MT. Proc Natl Acad Sci U S A 114 E9356-E9365 (2017)
  246. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. Donato E, Croci O, Sabò A, Muller H, Morelli MJ, Pelizzola M, Campaner S. Leukemia 31 479-490 (2017)
  247. Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Ballabio E, Milne TA. Cancers (Basel) 4 904-944 (2012)
  248. RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells. Jung KH, Das A, Chai JC, Kim SH, Morya N, Park KS, Lee YS, Chai YG. J Neuroinflammation 12 36 (2015)
  249. Structural insights into acetylated-histone H4 recognition by the bromodomain-PHD finger module of human transcriptional coactivator CBP. Plotnikov AN, Yang S, Zhou TJ, Rusinova E, Frasca A, Zhou MM. Structure 22 353-360 (2014)
  250. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis. Garrido Castro P, van Roon EHJ, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, Te Kronnie G, Heidenreich O, Pieters R, Stam RW. Leukemia 32 323-331 (2018)
  251. The chromatin Remodeler CHD8 is required for activation of progesterone receptor-dependent enhancers. Ceballos-Chávez M, Subtil-Rodríguez A, Giannopoulou EG, Soronellas D, Vázquez-Chávez E, Vicent GP, Elemento O, Beato M, Reyes JC. PLoS Genet 11 e1005174 (2015)
  252. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Fan-Minogue H, Bodapati S, Solow-Cordero D, Fan A, Paulmurugan R, Massoud TF, Felsher DW, Gambhir SS. Mol Cancer Ther 12 1896-1905 (2013)
  253. Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R. Oncoimmunology 7 e1398874 (2018)
  254. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation. Garcia-Carpizo V, Ruiz-Llorente S, Sarmentero J, Graña-Castro O, Pisano DG, Barrero MJ. Epigenetics Chromatin 11 30 (2018)
  255. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P. Cell Death Dis 7 e2365 (2016)
  256. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Chen X, Burkhardt DB, Hartman AA, Hu X, Eastman AE, Sun C, Wang X, Zhong M, Krishnaswamy S, Guo S. Nat Commun 10 5767 (2019)
  257. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR, Beesley AH. Oncogene 32 4664-4674 (2013)
  258. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Enomoto K, Zhu X, Park S, Zhao L, Zhu YJ, Willingham MC, Qi J, Copland JA, Meltzer P, Cheng SY. J Clin Endocrinol Metab 102 2268-2280 (2017)
  259. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. Oncotarget 9 29193-29207 (2018)
  260. ES cell-derived presomitic mesoderm-like tissues for analysis of synchronized oscillations in the segmentation clock. Matsumiya M, Tomita T, Yoshioka-Kobayashi K, Isomura A, Kageyama R. Development 145 dev156836 (2018)
  261. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status. Agarwal P, Jackson SP. Cancer Lett 380 467-475 (2016)
  262. Letter HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN. Leukemia 30 504-508 (2016)
  263. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B. Oncotarget 7 24125-24140 (2016)
  264. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators. Wai DCC, Szyszka TN, Campbell AE, Kwong C, Wilkinson-White LE, Silva APG, Low JKK, Kwan AH, Gamsjaeger R, Chalmers JD, Patrick WM, Lu B, Vakoc CR, Blobel GA, Mackay JP. J Biol Chem 293 7160-7175 (2018)
  265. The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D, Castellani G, Ambrosetti DC, Ciarrocchi A, Sancisi V. Oncogene 38 6801-6817 (2019)
  266. Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. Mazurek A, Park Y, Miething C, Wilkinson JE, Gillis J, Lowe SW, Vakoc CR, Stillman B. Cell Rep 7 1887-1899 (2014)
  267. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis. Roberts TC, Etxaniz U, Dall'Agnese A, Wu SY, Chiang CM, Brennan PE, Wood MJA, Puri PL. Sci Rep 7 6153 (2017)
  268. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC. Cancer Chemother Pharmacol 76 35-46 (2015)
  269. Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells. Huang X, Spencer GJ, Lynch JT, Ciceri F, Somerville TD, Somervaille TC. Leukemia 28 1081-1091 (2014)
  270. I-BET151 selectively regulates IL-6 production. Barrett E, Brothers S, Wahlestedt C, Beurel E. Biochim Biophys Acta 1842 1549-1555 (2014)
  271. MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Xu J, Li L, Xiong J, denDekker A, Ye A, Karatas H, Liu L, Wang H, Qin ZS, Wang S, Dou Y. Cell Discov 2 16008 (2016)
  272. Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SEW, Huntly BJ, Ottersbach K. Cell Rep 16 1039-1054 (2016)
  273. TIP60 represses activation of endogenous retroviral elements. Rajagopalan D, Tirado-Magallanes R, Bhatia SS, Teo WS, Sian S, Hora S, Lee KK, Zhang Y, Jadhav SP, Wu Y, Gan YH, Karnani N, Benoukraf T, Jha S. Nucleic Acids Res 46 9456-9470 (2018)
  274. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Gao Z, Yuan T, Zhou X, Ni P, Sun G, Li P, Cheng Z, Wang X. Cancer Biol Ther 19 407-415 (2018)
  275. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. Nakamura Y, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, Yoshino T, Ushijima T. Cancer Lett 402 100-109 (2017)
  276. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis. Osaki H, Walf-Vorderwülbecke V, Mangolini M, Zhao L, Horton SJ, Morrone G, Schuringa JJ, de Boer J, Williams O. Leukemia 27 1461-1468 (2013)
  277. The BET protein FSH functionally interacts with ASH1 to orchestrate global gene activity in Drosophila. Kockmann T, Gerstung M, Schlumpf T, Xhinzhou Z, Hess D, Beerenwinkel N, Beisel C, Paro R. Genome Biol 14 R18 (2013)
  278. BALR-6 regulates cell growth and cell survival in B-lymphoblastic leukemia. Rodríguez-Malavé NI, Fernando TR, Patel PC, Contreras JR, Palanichamy JK, Tran TM, Anguiano J, Davoren MJ, Alberti MO, Pioli KT, Sandoval S, Crooks GM, Rao DS. Mol Cancer 14 214 (2015)
  279. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK. Shafran JS, Andrieu GP, Györffy B, Denis GV. Mol Cancer Res 17 1627-1638 (2019)
  280. Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration. Ko S, Choi TY, Choi TY, Russell JO, So J, Monga SPS, Shin D. J Hepatol 64 316-325 (2016)
  281. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia. Garcia-Cuellar MP, Füller E, Mäthner E, Breitinger C, Hetzner K, Zeitlmann L, Borkhardt A, Slany RK. Leukemia 28 1427-1435 (2014)
  282. Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Hu Z, Zhou J, Jiang J, Yuan J, Zhang Y, Wei X, Loo N, Wang Y, Pan Y, Zhang T, Zhong X, Long M, Montone KT, Tanyi JL, Fan Y, Wang TL, Shih IM, Hu X, Zhang L. Nat Commun 10 733 (2019)
  283. Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2. Kinkel SA, Galeev R, Flensburg C, Keniry A, Breslin K, Gilan O, Lee S, Liu J, Chen K, Gearing LJ, Moore DL, Alexander WS, Dawson M, Majewski IJ, Oshlack A, Larsson J, Blewitt ME. Blood 125 1890-1900 (2015)
  284. Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours. Avgustinova A, Symeonidi A, Castellanos A, Urdiroz-Urricelqui U, Solé-Boldo L, Martín M, Pérez-Rodríguez I, Prats N, Lehner B, Supek F, Benitah SA. Nat Cell Biol 20 1400-1409 (2018)
  285. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F. Br J Haematol 178 936-948 (2017)
  286. BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells. Li J, Ma J, Meng G, Lin H, Wu S, Wang J, Luo J, Xu X, Tough D, Lindon M, Rioja I, Zhao J, Mei H, Prinjha R, Zhong Z. Stem Cell Res 17 212-221 (2016)
  287. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C. Exp Neurol 271 241-250 (2015)
  288. Interrogating Histone Acetylation and BRD4 as Mitotic Bookmarks of Transcription. Behera V, Stonestrom AJ, Hamagami N, Hsiung CC, Keller CA, Giardine B, Sidoli S, Yuan ZF, Bhanu NV, Werner MT, Wang H, Garcia BA, Hardison RC, Blobel GA. Cell Rep 27 400-415.e5 (2019)
  289. The Cornelia de Lange Syndrome-associated factor NIPBL interacts with BRD4 ET domain for transcription control of a common set of genes. Luna-Peláez N, March-Díaz R, Ceballos-Chávez M, Guerrero-Martínez JA, Grazioli P, García-Gutiérrez P, Vaccari T, Massa V, Reyes JC, García-Domínguez M. Cell Death Dis 10 548 (2019)
  290. BET Bromodomain Inhibitors Suppress Inflammatory Activation of Gingival Fibroblasts and Epithelial Cells From Periodontitis Patients. Maksylewicz A, Bysiek A, Lagosz KB, Macina JM, Kantorowicz M, Bereta G, Sochalska M, Gawron K, Chomyszyn-Gajewska M, Potempa J, Grabiec AM. Front Immunol 10 933 (2019)
  291. Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. Sutherell CL, Tallant C, Monteiro OP, Yapp C, Fuchs JE, Fedorov O, Siejka P, Müller S, Knapp S, Brenton JD, Brennan PE, Ley SV. J Med Chem 59 5095-5101 (2016)
  292. Identification of hidden relationships from the coupling of hydrophobic cluster analysis and domain architecture information. Faure G, Callebaut I. Bioinformatics 29 1726-1733 (2013)
  293. The Role of Bromodomain and Extraterminal Motif (BET) Proteins in Chromatin Structure. Hsu SC, Blobel GA. Cold Spring Harb Symp Quant Biol 82 37-43 (2017)
  294. Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells. Fujinaga K, Luo Z, Schaufele F, Peterlin BM. J Biol Chem 290 1829-1836 (2015)
  295. A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ. J Exp Med 212 1551-1569 (2015)
  296. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T, Wang G, Chen W, Zhu Z, Liu Y, Huang Z, Huang Y, Du P, Yang Y, Liu CY, Cui L. Cell Death Dis 9 315 (2018)
  297. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Huang Y, Nahar S, Nakagawa A, Fernandez-Barrena MG, Mertz JA, Bryant BM, Adams CE, Mino-Kenudson M, Von Alt KN, Chang K, Conery AR, Hatton C, Sims RJ, Fernandez-Zapico ME, Wang X, Lillemoe KD, Fernández-Del Castillo C, Warshaw AL, Thayer SP, Liss AS. Clin Cancer Res 22 4259-4270 (2016)
  298. The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. Hay D, Fedorov O, Filippakopoulos P, Martin S, Philpott M, Picaud S, Hewings DS, Uttakar S, Heightman TD, Conway SJ, Knapp S, Brennan PE. Medchemcomm 4 140-144 (2013)
  299. BET Inhibition Improves NASH and Liver Fibrosis. Middleton SA, Rajpal N, Cutler L, Mander P, Rioja I, Prinjha RK, Rajpal D, Agarwal P, Kumar V. Sci Rep 8 17257 (2018)
  300. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. Zhong M, Gao R, Zhao R, Huang Y, Chen C, Li K, Yu X, Nie D, Chen Z, Liu X, Liu Z, Chen S, Lu Y, Yu Z, Wang L, Li P, Zeng C, Li Y. Cell Death Dis 13 671 (2022)
  301. Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations. Lee JH, Salci KR, Reid JC, Orlando L, Tanasijevic B, Shapovalova Z, Bhatia M. Stem Cells 35 2095-2102 (2017)
  302. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, Yuan S, Reynaga JM, Qi Y, Rico J, Yu S, Liu Y, Rokudai S, Palmisiano N, Meyer SE, Sung PJ, Wan L, Lan F, Garcia BA, Stanger BZ, Sykes DB, Blanco MA. Cancer Discov 12 792-811 (2022)
  303. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Au YZ, Gu M, De Braekeleer E, Gozdecka M, Aspris D, Tarumoto Y, Cooper J, Yu J, Ong SH, Chen X, Tzelepis K, Huntly BJP, Vassiliou G, Yusa K. Leukemia 35 1012-1022 (2021)
  304. Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors. Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA. Cancer Res 77 5395-5408 (2017)
  305. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. Xiong C, Masucci MV, Zhou X, Liu N, Zang X, Tolbert E, Zhao TC, Zhuang S. Oncotarget 7 69291-69308 (2016)
  306. ANP32A regulates histone H3 acetylation and promotes leukemogenesis. Yang X, Lu B, Sun X, Han C, Fu C, Xu K, Wang M, Li D, Chen Z, Opal P, Wen Q, Crispino JD, Wang QF, Huang Z. Leukemia 32 1587-1597 (2018)
  307. BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells. Schilderink R, Bell M, Reginato E, Patten C, Rioja I, Hilbers FW, Kabala PA, Reedquist KA, Tough DF, Tak PP, Prinjha RK, de Jonge WJ. Mol Immunol 79 66-76 (2016)
  308. Bromodomain inhibitor I-BET151 suppresses immune responses during fungal-immune interaction. Domínguez-Andrés J, Ferreira AV, Jansen T, Smithers N, Prinjha RK, Furze RC, Netea MG. Eur J Immunol 49 2044-2050 (2019)
  309. Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma. Lefèvre L, Omeiri H, Drougat L, Hantel C, Giraud M, Val P, Rodriguez S, Perlemoine K, Blugeon C, Beuschlein F, de Reyniès A, Rizk-Rabin M, Bertherat J, Ragazzon B. Oncogenesis 4 e161 (2015)
  310. Double duty: ZMYND8 in the DNA damage response and cancer. Gong F, Miller KM. Cell Cycle 17 414-420 (2018)
  311. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Boudreaux SP, Duren RP, Call SG, Nguyen L, Freire PR, Narayanan P, Redell MS, Conneely OM. Leukemia 33 52-63 (2019)
  312. Dual transcriptome sequencing reveals resistance of TLR4 ligand-activated bone marrow-derived macrophages to inflammation mediated by the BET inhibitor JQ1. Das A, Chai JC, Yang CS, Lee YS, Das ND, Jung KH, Chai YG. Sci Rep 5 16932 (2015)
  313. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. Liu S, Wang Y, Han Y, Xia W, Zhang L, Xu S, Ju H, Zhang X, Ren G, Liu L, Ye W, Zhang Z, Hu J. Theranostics 10 10589-10605 (2020)
  314. General mechanism of JQ1 in inhibiting various types of cancer. Jiang G, Deng W, Liu Y, Wang C. Mol Med Rep 21 1021-1034 (2020)
  315. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. Muvva C, Singam ER, Raman SS, Subramanian V. Mol Biosyst 10 2384-2397 (2014)
  316. Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma. Wu Y, Wang Y, Diao P, Zhang W, Li J, Ge H, Song Y, Li Z, Wang D, Liu L, Jiang H, Cheng J. Theranostics 9 1777-1793 (2019)
  317. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Li J, Galbo PM, Gong W, Storey AJ, Tsai YH, Yu X, Ahn JH, Guo Y, Mackintosh SG, Edmondson RD, Byrum SD, Farrar JE, He S, Cai L, Jin J, Tackett AJ, Zheng D, Wang GG. Nat Commun 12 1045 (2021)
  318. Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin. Jones DH, Lin DI. Mol Clin Oncol 7 301-307 (2017)
  319. An in vivo molecular response analysis of colorectal cancer treated with Astragalus membranaceus extract. Tseng A, Yang CH, Chen CH, Chen CH, Hsu SL, Lee MH, Lee HC, Su LJ. Oncol Rep 35 659-668 (2016)
  320. BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. Ni M, Li J, Zhao H, Xu F, Cheng J, Yu M, Ke G, Wu X. Oncogene 40 2711-2724 (2021)
  321. BRD4 regulates self-renewal ability and tumorigenicity of glioma-initiating cells by enrichment in the Notch1 promoter region. Tao Z, Li X, Wang H, Chen G, Feng Z, Wu Y, Yin H, Zhao G, Deng Z, Zhao C, Li Y, Sun T, Zhou Y. Clin Transl Med 10 e181 (2020)
  322. Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification. Fernandez-Alonso R, Davidson L, Hukelmann J, Zengerle M, Prescott AR, Lamond A, Ciulli A, Sapkota GP, Findlay GM. EMBO Rep 18 1108-1122 (2017)
  323. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1. Zhang C, Su ZY, Wang L, Shu L, Yang Y, Guo Y, Pung D, Bountra C, Kong AN. Biochem Pharmacol 117 35-45 (2016)
  324. Epigenetic therapy of hematological malignancies: where are we now? Popovic R, Shah MY, Licht JD. Ther Adv Hematol 4 81-91 (2013)
  325. High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility. Pattenden SG, Simon JM, Wali A, Jayakody CN, Troutman J, McFadden AW, Wooten J, Wood CC, Frye SV, Janzen WP, Davis IJ. Proc Natl Acad Sci U S A 113 3018-3023 (2016)
  326. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T. Oncotarget 5 4257-4268 (2014)
  327. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma. Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Cancer Res 79 2415-2425 (2019)
  328. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Kim SK, Knight DA, Jones LR, Vervoort S, Ng AP, Seymour JF, Bradner JE, Waibel M, Kats L, Johnstone RW. Genes Dev 32 849-864 (2018)
  329. Naphthyridines as novel BET family bromodomain inhibitors. Mirguet O, Lamotte Y, Chung CW, Bamborough P, Delannée D, Bouillot A, Gellibert F, Krysa G, Lewis A, Witherington J, Huet P, Dudit Y, Trottet L, Nicodeme E. ChemMedChem 9 580-589 (2014)
  330. Selective BET bromodomain inhibition as an antifungal therapeutic strategy. Mietton F, Ferri E, Champleboux M, Zala N, Maubon D, Zhou Y, Harbut M, Spittler D, Garnaud C, Courçon M, Chauvel M, d'Enfert C, Kashemirov BA, Hull M, Cornet M, McKenna CE, Govin J, Petosa C. Nat Commun 8 15482 (2017)
  331. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors. Call SG, Duren RP, Panigrahi AK, Nguyen L, Freire PR, Grimm SL, Coarfa C, Conneely OM. Sci Rep 10 2851 (2020)
  332. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. Sun Y, Fan J, Wang B, Meng Z, Ren D, Zhao J, Liu Z, Li D, Jin X, Wu H. Am J Cancer Res 10 148-163 (2020)
  333. BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Xu Z, Sharp PP, Yao Y, Segal D, Ang CH, Khaw SL, Aubrey BJ, Gong J, Kelly GL, Herold MJ, Strasser A, Roberts AW, Alexander WS, Burns CJ, Huang DC, Glaser SP. Leukemia 30 1531-1541 (2016)
  334. Comment BRD4: a BET(ter) target for the treatment of AML? Valent P, Zuber J. Cell Cycle 13 689-690 (2014)
  335. Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. Pérez-Salvia M, Simó-Riudalbas L, Llinàs-Arias P, Roa L, Setien F, Soler M, de Moura MC, Bradner JE, Gonzalez-Suarez E, Moutinho C, Esteller M. Oncotarget 8 51621-51629 (2017)
  336. Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. Groves IJ, Jackson SE, Poole EL, Nachshon A, Rozman B, Schwartz M, Prinjha RK, Tough DF, Sinclair JH, Wills MR. Proc Natl Acad Sci U S A 118 e2023025118 (2021)
  337. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Romine KA, Nechiporuk T, Bottomly D, Jeng S, McWeeney SK, Kaempf A, Corces MR, Majeti R, Tyner JW. Blood Cancer Discov 2 518-531 (2021)
  338. Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation. Meier JC, Tallant C, Fedorov O, Witwicka H, Hwang SY, van Stiphout RG, Lambert JP, Rogers C, Yapp C, Gerstenberger BS, Fedele V, Savitsky P, Heidenreich D, Daniels DL, Owen DR, Fish PV, Igoe NM, Bayle ED, Haendler B, Oppermann UCT, Buffa F, Brennan PE, Müller S, Gingras AC, Odgren PR, Birnbaum MJ, Knapp S. ACS Chem Biol 12 2619-2630 (2017)
  339. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Cao Z, Budinich KA, Huang H, Ren D, Lu B, Zhang Z, Chen Q, Zhou Y, Huang YH, Alikarami F, Kingsley MC, Lenard AK, Wakabayashi A, Khandros E, Bailis W, Qi J, Carroll MP, Blobel GA, Faryabi RB, Bernt KM, Berger SL, Shi J. Mol Cell 81 3604-3622.e10 (2021)
  340. c-MYC partners with BPTF in human cancer. Richart L, Real FX, Sanchez-Arevalo Lobo VJ. Mol Cell Oncol 3 e1152346 (2016)
  341. miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. Meyer SE, Muench DE, Rogers AM, Newkold TJ, Orr E, O'Brien E, Perentesis JP, Doench JG, Lal A, Morris PJ, Thomas CJ, Lieberman J, McGlinn E, Aronow BJ, Salomonis N, Grimes HL. J Exp Med 215 2115-2136 (2018)
  342. miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein. Tonouchi E, Gen Y, Muramatsu T, Hiramoto H, Tanimoto K, Inoue J, Inazawa J. Sci Rep 8 4482 (2018)
  343. Acute perturbation strategies in interrogating RNA polymerase II elongation factor function in gene expression. Zheng B, Aoi Y, Shah AP, Iwanaszko M, Das S, Rendleman EJ, Zha D, Khan N, Smith ER, Shilatifard A. Genes Dev 35 273-285 (2021)
  344. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors. Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X. J Clin Invest 131 133090 (2021)
  345. BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation. Vershinin Z, Feldman M, Werner T, Weil LE, Kublanovsky M, Abaev-Schneiderman E, Sklarz M, Lam EYN, Alasad K, Picaud S, Rotblat B, McAdam RA, Chalifa-Caspi V, Bantscheff M, Chapman T, Lewis HD, Filippakopoulos P, Dawson MA, Grandi P, Prinjha RK, Levy D. Sci Adv 7 eabf5374 (2021)
  346. Discovery of RSV-Induced BRD4 Protein Interactions Using Native Immunoprecipitation and Parallel Accumulation-Serial Fragmentation (PASEF) Mass Spectrometry. Mann M, Roberts DS, Zhu Y, Li Y, Zhou J, Ge Y, Brasier AR. Viruses 13 454 (2021)
  347. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Blood 135 1255-1269 (2020)
  348. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, Failes TW, Arndt GM, Smithers N, Prinjha RK, Anderson D, Carter KW, Gout AM, Lassmann T, O'Reilly J, Cole CH, Kotecha RS, Kees UR. Leukemia 31 40-50 (2017)
  349. Congress The cancer genome: from structure to function. Geurts van Kessel A. Cell Oncol (Dordr) 37 155-165 (2014)
  350. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein PS, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A. Leukemia 33 2429-2441 (2019)
  351. A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma. Stirnweiss A, McCarthy K, Oommen J, Crook ML, Hardy K, Kees UR, Wilton SD, Anazodo A, Beesley AH. Oncogenesis 4 e174 (2015)
  352. AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia. Jiang Y, Hu T, Wang T, Shi X, Kitano A, Eagle K, Hoegenauer KA, Konopleva MY, Lin CY, Young NL, Nakada D. Blood 134 2183-2194 (2019)
  353. Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation. Gaub A, Sheikh BN, Basilicata MF, Vincent M, Nizon M, Colson C, Bird MJ, Bradner JE, Thevenon J, Boutros M, Akhtar A. Nat Commun 11 2243 (2020)
  354. News First drugs found to inhibit elusive cancer target. Moyer MW. Nat Med 17 1325 (2011)
  355. Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, Jarrard DF, Denu JM. ACS Chem Biol 12 2804-2814 (2017)
  356. MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation. Huang Y, Thoms JA, Tursky ML, Knezevic K, Beck D, Chandrakanthan V, Suryani S, Olivier J, Boulton A, Glaros EN, Thomas SR, Lock RB, MacKenzie KL, Bushweller JH, Wong JW, Pimanda JE. Leukemia 30 1552-1561 (2016)
  357. MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Wyce A, Matteo JJ, Foley SW, Felitsky DJ, Rajapurkar SR, Zhang XP, Musso MC, Korenchuk S, Karpinich NO, Keenan KM, Stern M, Mathew LK, McHugh CF, McCabe MT, Tummino PJ, Kruger RG, Carpenter C, Barbash O. Oncogenesis 7 35 (2018)
  358. Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression. Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A. J Natl Cancer Inst 106 dju043 (2014)
  359. New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition. Baud MG, Lin-Shiao E, Zengerle M, Tallant C, Ciulli A. J Med Chem 59 1492-1500 (2016)
  360. Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition. Runcie AC, Zengerle M, Chan KH, Testa A, van Beurden L, Baud MGJ, Epemolu O, Ellis LCJ, Read KD, Coulthard V, Brien A, Ciulli A. Chem Sci 9 2452-2468 (2018)
  361. Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains. Shao Z, Yao C, Khodadadi-Jamayran A, Xu W, Townes TM, Crowley MR, Hu K. Cell Rep 16 3138-3145 (2016)
  362. SWI/SNF proteins as targets in cancer therapy. Schiaffino-Ortega S, Balinas C, Cuadros M, Medina PP. J Hematol Oncol 7 81 (2014)
  363. The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. Piquereau J, Boet A, Péchoux C, Antigny F, Lambert M, Gressette M, Ranchoux B, Gambaryan N, Domergue V, Mumby S, Montani D, Adcock IM, Humbert M, Garnier A, Rucker-Martin C, Perros F. Int J Mol Sci 20 E1527 (2019)
  364. The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis. Tran TM, Philipp J, Bassi JS, Nibber N, Draper JM, Lin TL, Palanichamy JK, Jaiswal AK, Silva O, Paing M, King J, Katzman S, Sanford JR, Rao DS. Leukemia 36 68-79 (2022)
  365. Time series modeling of cell cycle exit identifies Brd4 dependent regulation of cerebellar neurogenesis. Penas C, Maloof ME, Stathias V, Long J, Tan SK, Mier J, Fang Y, Valdes C, Rodriguez-Blanco J, Chiang CM, Robbins DJ, Liebl DJ, Lee JK, Hatten ME, Clarke J, Ayad NG. Nat Commun 10 3028 (2019)
  366. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity. Khoueiry P, Ward Gahlawat A, Petretich M, Michon AM, Simola D, Lam E, Furlong EE, Benes V, Dawson MA, Prinjha RK, Drewes G, Grandi P. Epigenetics Chromatin 12 39 (2019)
  367. BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression. Wu Q, Liu F, Ge M, Laster KV, Wei L, Du R, Jiang M, Zhang J, Zhi Y, Jin G, Zhao S, Kim DJ, Dong Z, Liu K. Oncogene 41 347-360 (2022)
  368. Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762. Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT. Cancer Prev Res (Phila) 11 143-156 (2018)
  369. Cis-acting lnc-eRNA SEELA directly binds histone H4 to promote histone recognition and leukemia progression. Fang K, Huang W, Sun YM, Chen TQ, Zeng ZC, Yang QQ, Pan Q, Han C, Sun LY, Luo XQ, Wang WT, Chen YQ. Genome Biol 21 269 (2020)
  370. Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells. Murakami S, Li R, Nagari A, Chae M, Camacho CV, Kraus WL. Mol Cancer Res 17 2356-2368 (2019)
  371. Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells. Domingues AF, Kulkarni R, Giotopoulos G, Gupta S, Vinnenberg L, Arede L, Foerner E, Khalili M, Adao RR, Johns A, Tan S, Zeka K, Huntly BJ, Prabakaran S, Pina C. Elife 9 e51754 (2020)
  372. Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies. Lasorsa E, Smonksey M, Kirk JS, Rosario S, Hernandez-Ilizaliturri FJ, Ellis L. Cell Death Dis 6 e2014 (2015)
  373. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors. Raj U, Kumar H, Varadwaj PK. J Biomol Struct Dyn 35 2351-2362 (2017)
  374. Pharmacological Inhibition of Bromodomain Proteins Suppresses Retinal Inflammatory Disease and Downregulates Retinal Th17 Cells. Eskandarpour M, Alexander R, Adamson P, Calder VL. J Immunol 198 1093-1103 (2017)
  375. Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia. Fang Y, Yang Y, Hua C, Xu S, Zhou M, Guo H, Wang N, Zhao X, Huang L, Yu F, Cheng H, Wang ML, Meng L, Cheng T, Yuan W, Ma D, Zhou J. Leukemia 31 414-422 (2017)
  376. Scaling the druggability landscape of human bromodomains, a new class of drug targets. Zhang G, Sanchez R, Zhou MM. J Med Chem 55 7342-7345 (2012)
  377. Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. Nakagawa A, Adams CE, Huang Y, Hamarneh SR, Liu W, Von Alt KN, Mino-Kenudson M, Hodin RA, Lillemoe KD, Fernández-Del Castillo C, Warshaw AL, Liss AS. Sci Rep 6 20390 (2016)
  378. Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. Zhao Y, Bai L, Liu L, McEachern D, Stuckey JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. J Med Chem 60 3887-3901 (2017)
  379. Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. Kitazawa S, Ebara S, Ando A, Baba Y, Satomi Y, Soga T, Hara T. Oncotarget 8 28922-28938 (2017)
  380. Targeted drug discovery for pediatric leukemia. Napper AD, Watson VG. Front Oncol 3 170 (2013)
  381. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. Leukemia 34 1588-1598 (2020)
  382. The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis. Shao Z, Zhang R, Khodadadi-Jamayran A, Chen B, Crowley MR, Festok MA, Crossman DK, Townes TM, Hu K. Nat Commun 7 10869 (2016)
  383. The bromodomain protein BRD4 positively regulates necroptosis via modulating MLKL expression. Xiong Y, Li L, Zhang L, Cui Y, Wu C, Li H, Chen K, Yang Q, Xiang R, Hu Y, Huang S, Wei Y, Yang S. Cell Death Differ 26 1929-1941 (2019)
  384. Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival. Ucar D, Lin DI. Mol Clin Oncol 3 1291-1294 (2015)
  385. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression. Shi C, Yang EJ, Liu Y, Mou PK, Ren G, Shim JS. Oncogene 40 937-950 (2021)
  386. Bromodomains: are readers right for epigenetic therapy? Conway SJ. ACS Med Chem Lett 3 691-694 (2012)
  387. Can cancer researchers accurately judge whether preclinical reports will reproduce? Benjamin D, Mandel DR, Kimmelman J. PLoS Biol 15 e2002212 (2017)
  388. Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. Wingelhofer B, Somervaille TCP. Front Oncol 9 850 (2019)
  389. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia. Wu Z, Eguchi-Ishimae M, Yagi C, Iwabuki H, Gao W, Tauchi H, Inukai T, Sugita K, Ishii E, Eguchi M. Br J Haematol 171 818-829 (2015)
  390. LYAR potentiates rRNA synthesis by recruiting BRD2/4 and the MYST-type acetyltransferase KAT7 to rDNA. Izumikawa K, Ishikawa H, Yoshikawa H, Fujiyama S, Watanabe A, Aburatani H, Tachikawa H, Hayano T, Miura Y, Isobe T, Simpson RJ, Li L, Min J, Takahashi N. Nucleic Acids Res 47 10357-10372 (2019)
  391. Mechanisms of mixed-lineage leukemia. Muntean AG. Int J Hematol Oncol 2 207-217 (2013)
  392. Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors. Cooper JM, Patel AJ, Chen Z, Liao CP, Chen K, Mo J, Wang Y, Le LQ. Clin Cancer Res 25 3404-3416 (2019)
  393. SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance. Cruickshank VA, Sroczynska P, Sankar A, Miyagi S, Rundsten CF, Johansen JV, Helin K. PLoS One 10 e0142806 (2015)
  394. The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation. Zhang XX, Lin J, Liang TZ, Duan H, Tan XH, Xi BM, Li L, Liu SW. Acta Pharmacol Sin 40 98-110 (2019)
  395. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G, AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’. Oncotarget 7 79637-79653 (2016)
  396. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. Xu C, Meng F, Park KS, Storey AJ, Gong W, Tsai YH, Gibson E, Byrum SD, Li D, Edmondson RD, Mackintosh SG, Vedadi M, Cai L, Tackett AJ, Kaniskan HÜ, Jin J, Wang GG. Cell Chem Biol 29 386-397.e9 (2022)
  397. BRD4 jump-starts transcription after mitotic silencing. Voigt P, Reinberg D. Genome Biol 12 133 (2011)
  398. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. Cribbs AP, Filippakopoulos P, Philpott M, Wells G, Penn H, Oerum H, Valge-Archer V, Feldmann M, Oppermann U. Front Immunol 12 626255 (2021)
  399. Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1. Galoian K, Qureshi A, D'Ippolito G, Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC, Temple HT. Int J Oncol 47 465-472 (2015)
  400. Epigenetics: Reading the second genomic code. Marx V. Nature 491 143-147 (2012)
  401. Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells. Du Z, Song X, Yan F, Wang J, Zhao Y, Liu S. Int J Oncol 52 1415-1426 (2018)
  402. The "histone mimicry" by pathogens. Schaefer U, Ho JS, Prinjha RK, Tarakhovsky A. Cold Spring Harb Symp Quant Biol 78 81-90 (2013)
  403. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. Lee M, Tayyari F, Pinnaduwage D, Bayani J, Bartlett JMS, Mulligan AM, Bull SB, Andrulis IL. BMC Cancer 18 750 (2018)
  404. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc. Li N, Yang L, Qi XK, Lin YX, Xie X, He GP, Feng QS, Liu LR, Xie X, Zeng YX, Feng L. Cell Death Dis 9 761 (2018)
  405. BETs abet Tam-R in ER-positive breast cancer. Alluri PG, Asangani IA, Chinnaiyan AM. Cell Res 24 899-900 (2014)
  406. Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, James KS, Sutton C, Sanchez A, Emery A, Sampey G, Ferris R, Allard B, Ghofrani S, Kirchherr JL, Baker C, Kuruc JD, Gay CL, James LI, Wu G, Zuck P, Rioja I, Furze RC, Prinjha RK, Howell BJ, Swanstrom R, Browne EP, Strahl BD, Dunham RM, Archin NM, Margolis DM. J Clin Invest 132 e157281 (2022)
  407. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system. Werner MT, Wang H, Hamagami N, Hsu SC, Yano JA, Stonestrom AJ, Behera V, Zong Y, Mackay JP, Blobel GA. J Biol Chem 295 1898-1914 (2020)
  408. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, Belloucif Y, Laiguillon MC, Meduri E, Vaganay C, Alexe G, Berrou J, Benaksas C, Forget A, Braun T, Gardin C, Raffoux E, Clappier E, Adès L, de Thé H, Fenaille F, Huntly BJ, Stegmaier K, Dombret H, Fenouille N, Lobry C, Puissant A, Itzykson R. Leukemia 36 1585-1595 (2022)
  409. Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain. Ma XR, Xu L, Xu S, Klein BJ, Wang H, Das S, Li K, Yang KS, Sohail S, Chapman A, Kutateladze TG, Shi X, Liu WR, Wen H. J Med Chem 64 10997-11013 (2021)
  410. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues. Jiang H, Xing J, Wang C, Zhang H, Yue L, Wan X, Chen W, Ding H, Xie Y, Tao H, Chen Z, Jiang H, Chen K, Chen S, Zheng M, Zhang Y, Luo C. Org Biomol Chem 15 9352-9361 (2017)
  411. Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Douglas JK, Callahan RE, Hothem ZA, Cousineau CS, Kawak S, Thibodeau BJ, Bergeron S, Li W, Peeples CE, Wasvary HJ. Mol Cell Oncol 7 1716618 (2020)
  412. Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation. Ran T, Zhang Z, Liu K, Lu Y, Li H, Xu J, Xiong X, Zhang Y, Xu A, Lu S, Liu H, Lu T, Chen Y. Mol Biosyst 11 1295-1304 (2015)
  413. Link Between ER-Stress, PPAR-Alpha Activation, and BET Inhibition in Relation to Apolipoprotein A-I Transcription in HepG2 Cells. van der Krieken SE, Popeijus HE, Mensink RP, Plat J. J Cell Biochem 118 2161-2167 (2017)
  414. New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy. Khan I, Altman JK, Licht JD. Clin Cancer Res 18 5163-5171 (2012)
  415. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling. Grundy M, Seedhouse C, Jones T, Elmi L, Hall M, Graham A, Russell N, Pallis M. PLoS One 13 e0190682 (2018)
  416. Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines. Wanner J, Romashko D, Werner DS, May EW, Peng Y, Schulz R, Foreman KW, Russo S, Arnold LD, Pingle M, Bergstrom DE, Barany F, Thomson S. PLoS One 10 e0121793 (2015)
  417. Structure-function relationships explain CTCF zinc finger mutation phenotypes in cancer. Bailey CG, Gupta S, Metierre C, Amarasekera PMS, O'Young P, Kyaw W, Laletin T, Francis H, Semaan C, Sharifi Tabar M, Singh KP, Mullighan CG, Wolkenhauer O, Schmitz U, Rasko JEJ. Cell Mol Life Sci 78 7519-7536 (2021)
  418. Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1. Decker TM, Kluge M, Krebs S, Shah N, Blum H, Friedel CC, Eick D. Sci Rep 7 1684 (2017)
  419. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy. Lao Z, Yiu R, Wong GC, Ho A. Asia Pac J Clin Oncol 11 54-61 (2015)
  420. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Hofving T, Sandblom V, Arvidsson Y, Shubbar E, Altiparmak G, Swanpalmer J, Almobarak B, Elf AK, Johanson V, Elias E, Kristiansson E, Forssell-Aronsson E, Nilsson O. Endocr Relat Cancer 26 437-449 (2019)
  421. 7SK small nuclear RNA transcription level down-regulates in human tumors and stem cells. Abasi M, Bazi Z, Mohammadi-Yeganeh S, Soleimani M, Haghpanah V, Zargami N, Ghanbarian H. Med Oncol 33 128 (2016)
  422. A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes. Harman JR, Thorne R, Jamilly M, Tapia M, Crump NT, Rice S, Beveridge R, Morrissey E, de Bruijn MFTR, Roberts I, Roy A, Fulga TA, Milne TA. Genome Res 31 1159-1173 (2021)
  423. A global transcriptomic pipeline decoding core network of genes involved in stages leading to acquisition of drug-resistance to cisplatin in osteosarcoma cells. Niveditha D, Mukherjee S, Majumder S, Chowdhury R, Chowdhury S. Bioinformatics 35 1701-1711 (2019)
  424. Acute Systemic Inflammatory Response Alters Transcription Profile of Genes Related to Immune Response and Ca2+ Homeostasis in Hippocampus; Relevance to Neurodegenerative Disorders. Czapski GA, Zhao Y, Lukiw WJ, Strosznajder JB. Int J Mol Sci 21 E7838 (2020)
  425. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo. Morse MA, Balogh KK, Brendle SA, Campbell CA, Chen MX, Furze RC, Harada IL, Holyer ID, Kumar U, Lee K, Prinjha RK, Rüdiger M, Seal JT, Taylor S, Witherington J, Christensen ND. Antiviral Res 154 158-165 (2018)
  426. Congress Barcelona Conference on Epigenetics and Cancer: 50 years of histone acetylation. Perez-Salvia M, Simó-Riudalbas L, Ausió J, Esteller M. Epigenetics 10 446-451 (2015)
  427. Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease. Manni ML, Mandalapu S, Salmeron A, Lora JM, Kolls JK, Alcorn JF. Sci Rep 7 43139 (2017)
  428. Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. Badamchi-Zadeh A, Moynihan KD, Larocca RA, Aid M, Provine NM, Iampietro MJ, Kinnear E, Penaloza-MacMaster P, Abbink P, Blass E, Tregoning JS, Irvine DJ, Barouch DH. J Immunol 201 2744-2752 (2018)
  429. Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. Merker JD, Roskin KM, Ng D, Pan C, Fisk DG, King JJ, Hoh R, Stadler M, Okumoto LM, Abidi P, Hewitt R, Jones CD, Gojenola L, Clark MJ, Zhang B, Cherry AM, George TI, Snyder M, Boyd SD, Zehnder JL, Fire AZ, Gotlib J. Haematologica 98 1689-1696 (2013)
  430. Development of methyl isoxazoleazepines as inhibitors of BET. Hewitt MC, Leblanc Y, Gehling VS, Vaswani RG, Côté A, Nasveschuk CG, Taylor AM, Harmange JC, Audia JE, Pardo E, Cummings R, Joshi S, Sandy P, Mertz JA, Sims RJ, Bergeron L, Bryant BM, Bellon S, Poy F, Jayaram H, Tang Y, Albrecht BK. Bioorg Med Chem Lett 25 1842-1848 (2015)
  431. Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins. Malvezzi F, Stubbs CJ, Jowitt TA, Dale IL, Guo X, DeGnore JP, Degliesposti G, Skehel JM, Bannister AJ, McAlister MS. Commun Biol 4 1273 (2021)
  432. Report of the First International Symposium on NUT Carcinoma. French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI. Clin Cancer Res 28 2493-2505 (2022)
  433. Letter Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia. Zhu S, Cheng X, Wang R, Tan Y, Ge M, Li D, Xu Q, Sun Y, Zhao C, Chen S, Liu H. Leukemia 34 2484-2488 (2020)
  434. Small molecules remain on target for c-Myc. Sun L, Gao P. Elife 6 e22915 (2017)
  435. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors. Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L. Bioorg Med Chem Lett 27 4051-4055 (2017)
  436. The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network. Liu J, Li F, Bao H, Jiang Y, Zhang S, Ma R, Gao J, Wu J, Ruan K. FEBS J 284 1082-1095 (2017)
  437. Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4. Francisco JC, Dai Q, Luo Z, Wang Y, Chong RH, Tan YJ, Xie W, Lee GH, Lin C. Mol Cell Biol 37 e00040-17 (2017)
  438. Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET. Koblan LW, Buckley DL, Ott CJ, Fitzgerald ME, Ember SW, Zhu JY, Liu S, Roberts JM, Remillard D, Vittori S, Zhang W, Schonbrunn E, Bradner JE. ChemMedChem 11 2575-2581 (2016)
  439. Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Huang M, Zhu L, Garcia JS, Li MX, Gentles AJ, Mitchell BS. Oncotarget 9 11665-11676 (2018)
  440. CDK6, a new target in MLL-driven leukemia. Antony-Debré I, Steidl U. Blood 124 5-6 (2014)
  441. Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma. Richter GHS, Hensel T, Schmidt O, Saratov V, von Heyking K, Becker-Dettling F, Prexler C, Yen HY, Steiger K, Fulda S, Dirksen U, Weichert W, Wang S, Burdach S, Schäfer BW. Cancers (Basel) 12 E304 (2020)
  442. Human expandable pancreatic progenitor-derived β cells ameliorate diabetes. Ma X, Lu Y, Zhou Z, Li Q, Chen X, Wang W, Jin Y, Hu Z, Chen G, Deng Q, Shang W, Wang H, Fu H, He X, Feng XH, Zhu S. Sci Adv 8 eabk1826 (2022)
  443. Musashi1 Contribution to Glioblastoma Development via Regulation of a Network of DNA Replication, Cell Cycle and Division Genes. Baroni M, Yi C, Choudhary S, Lei X, Kosti A, Grieshober D, Velasco M, Qiao M, Burns SS, Araujo PR, DeLambre T, Son MY, Plateroti M, Ferreira MAR, Hasty P, Penalva LOF. Cancers (Basel) 13 1494 (2021)
  444. Structural plasticity of the TDRD3 Tudor domain probed by a fragment screening hit. Liu J, Zhang S, Liu M, Liu Y, Nshogoza G, Gao J, Ma R, Yang Y, Wu J, Zhang J, Li F, Ruan K. FEBS J 285 2091-2103 (2018)
  445. The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability. Grey W, Ivey A, Milne TA, Haferlach T, Grimwade D, Uhlmann F, Voisset E, Yu V. Biochim Biophys Acta Mol Cell Res 1865 105-116 (2018)
  446. XB130: A novel adaptor protein in cancer signal transduction. Zhang R, Zhang J, Wu Q, Meng F, Liu C. Biomed Rep 4 300-306 (2016)
  447. BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation. Gao F, Yang Y, Wang Z, Gao X, Zheng B. Cell Immunol 294 1-8 (2015)
  448. Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis. Wang R, Yang JF, Ho F, Robertson ES, You J. Cancers (Basel) 12 E1637 (2020)
  449. Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. Gehringer M, Laufer SA. Angew Chem Int Ed Engl 56 15504-15505 (2017)
  450. Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma. Chen W, Zhang H, Chen Z, Jiang H, Liao L, Fan S, Xing J, Xie Y, Chen S, Ding H, Chen K, Jiang H, Luo C, Zheng M, Yao Z, Huang Y, Zhang Y. Oncogenesis 7 83 (2018)
  451. Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors. Martin RD, Sun Y, MacKinnon S, Cuccia L, Pagé V, Hébert TE, Tanny JC. Mol Cell Biol 40 e00048-20 (2020)
  452. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors. Noguchi-Yachide T, Sakai T, Hashimoto Y, Yamaguchi T. Bioorg Med Chem 23 953-959 (2015)
  453. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment. Ali I, Lee J, Go A, Choi G, Lee K. Bioorg Med Chem Lett 27 4606-4613 (2017)
  454. Epigenetic reader SP140 loss of function drives Crohn's disease due to uncontrolled macrophage topoisomerases. Amatullah H, Fraschilla I, Digumarthi S, Huang J, Adiliaghdam F, Bonilla G, Wong LP, Rivard ME, Beauchamp C, Mercier V, Goyette P, Sadreyev RI, Anthony RM, Rioux JD, Jeffrey KL. Cell 185 3232-3247.e18 (2022)
  455. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS. Sci Rep 11 13158 (2021)
  456. Maintenance of muscle myosin levels in adult C. elegans requires both the double bromodomain protein BET-1 and sumoylation. Fisher K, Gee F, Wang S, Xue F, Knapp S, Philpott M, Wells C, Rodriguez M, Snoek LB, Kammenga J, Poulin GB. Biol Open 2 1354-1363 (2013)
  457. NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains. Wang N, Li F, Bao H, Li J, Wu J, Ruan K. Chembiochem 17 1456-1463 (2016)
  458. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Fung JJ, Kosaka A, Shan X, Danet-Desnoyers G, Gormally M, Owen K, Reproducibility Project: Cancer Biology, Reproducibility Project Cancer Biology. Elife 4 (2015)
  459. Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4. Calder J, Nagelberg A, Luu J, Lu D, Lockwood WW. Oncogenesis 10 27 (2021)
  460. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Liu PY, Sokolowski N, Guo ST, Siddiqi F, Atmadibrata B, Telfer TJ, Sun Y, Zhang L, Yu D, Mccarroll J, Liu B, Yang RH, Guo XY, Tee AE, Itoh K, Wang J, Kavallaris M, Haber M, Norris MD, Cheung BB, Byrne JA, Ziegler DS, Marshall GM, Dinger ME, Codd R, Zhang XD, Liu T. Oncotarget 7 79217-79232 (2016)
  461. The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells. van Gils N, Martiañez Canales T, Vermue E, Rutten A, Denkers F, van der Deure T, Ossenkoppele GJ, Giles F, Smit L. Hemasphere 5 e610 (2021)
  462. The second coming of epigenetic drugs: a more strategic and broader research framework could boost the development of new drugs to modify epigenetic factors and gene expression. Hunter P. EMBO Rep 16 276-279 (2015)
  463. BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML. Zhang S, Zhao Y, Heaster TM, Fischer MA, Stengel KR, Zhou X, Ramsey H, Zhou MM, Savona MR, Skala MC, Hiebert SW. J Cell Biochem 120 7309-7322 (2019)
  464. BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. Tsukamoto T, Nakahata S, Sato R, Kanai A, Nakano M, Chinen Y, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Mizuno Y, Kuwahara-Ota S, Kawaji Y, Taniwaki M, Inaba T, Tashiro K, Morishita K, Kuroda J. Cancer Genomics Proteomics 17 77-89 (2020)
  465. Bi-directional regulation of cartilage metabolism by inhibiting BET proteins-analysis of the effect of I-BET151 on human chondrocytes and murine joints. Dai J, Zhou S, Ge Q, Qin J, Chen D, Xu Z, Shi D, Li J, Ju H, Cao Y, Zheng M, Li CJ, Gao X, Teng H, Jiang Q. J Orthop Surg Res 13 118 (2018)
  466. Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma. Zhu Y, Yang W, Ji G, Lin N, Wu W, Xiong P, Zheng C, Yan L, Wan P, Wang Y. Oncotarget 8 31092-31100 (2017)
  467. Cohesin couples transcriptional bursting probabilities of inducible enhancers and promoters. Robles-Rebollo I, Cuartero S, Canellas-Socias A, Wells S, Karimi MM, Mereu E, Chivu AG, Heyn H, Whilding C, Dormann D, Marguerat S, Rioja I, Prinjha RK, Stumpf MPH, Fisher AG, Merkenschlager M. Nat Commun 13 4342 (2022)
  468. Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Matissek SJ, Han W, Karbalivand M, Sayed M, Reilly BM, Mallat S, Ghazal SM, Munshi M, Yang G, Treon SP, Walker SR, Elsawa SF. Epigenomics 13 129-144 (2021)
  469. Congress First Barcelona Conference on Epigenetics and Cancer. Palau A, Perucho M, Esteller M, Buschbeck M. Epigenetics 9 468-475 (2014)
  470. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia. Takachi T, Watanabe T, Miyamura T, Moriya Saito A, Deguchi T, Hori T, Yamada T, Ohmori S, Haba M, Aoki Y, Ishimaru S, Sasaki S, Ohshima J, Iguchi A, Takahashi Y, Hyakuna N, Manabe A, Horibe K, Ishii E, Koh K, Tomizawa D. Blood Adv 5 3891-3899 (2021)
  471. Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Shan X, Fung JJ, Kosaka A, Danet-Desnoyers G, Reproducibility Project: Cancer Biology. Elife 6 e25306 (2017)
  472. Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia. Liu Y, Li Q, Alikarami F, Barrett DR, Mahdavi L, Li H, Tang S, Khan TA, Michino M, Hill C, Song L, Yang L, Li Y, Pokharel SP, Stamford AW, Liverton N, Renzetti LM, Taylor S, Watt GF, Ladduwahetty T, Kargman S, Meinke PT, Foley MA, Shi J, Li H, Carroll M, Chen CW, Gardini A, Maillard I, Huggins DJ, Bernt KM, Wan L. Cancer Discov 12 2684-2709 (2022)
  473. Research Support, Non-U.S. Gov't Targeting the BET family for the treatment of leukemia. Lucas X, Günther S. Epigenomics 6 153-155 (2014)
  474. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G. Leukemia 36 1261-1273 (2022)
  475. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. J Proteomics 233 104046 (2021)
  476. The emerging spectrum of early life exposure-related inflammation and epigenetic therapy. Yang Q, Ali M, El Andaloussi A, Al-Hendy A. Cancer Stud Mol Med 4 13-23 (2018)
  477. Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition. Bishop TR, Subramanian C, Bilotta EM, Garnar-Wortzel L, Ramos AR, Zhang Y, Asiaban JN, Ott CJ, Rock CO, Erb MA. Nat Chem Biol 19 1215-1222 (2023)
  478. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KPA, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J, Blazar BR. Blood 139 2983-2997 (2022)
  479. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia. Sang X, Zhang Y, Fang F, Gao L, Tao Y, Li X, Zhang Z, Wang J, Tian Y, Li Z, Yao D, Wu Y, Chu X, Zhang K, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Zhang Z, Pan J, Hu S. J Immunol Res 2022 7912484 (2022)
  480. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Wang L, Matkar S, Xie G, An C, He X, Kong X, Liu X, Hua X. Cancer Biol Ther 18 229-236 (2017)
  481. Brd/BET Proteins Influence the Genome-Wide Localization of the Kaposi's Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus Major Latency Proteins. Lotke R, Schneeweiß U, Pietrek M, Günther T, Grundhoff A, Weidner-Glunde M, Schulz TF. Front Microbiol 11 591778 (2020)
  482. Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration. Russell JO, Ko S, Saggi HS, Singh S, Poddar M, Shin D, Monga SP. Am J Pathol 188 1389-1405 (2018)
  483. Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies. Altenburg B, Frings M, Schöbel JH, Goßen J, Pannen K, Vanderliek K, Rossetti G, Koschmieder S, Chatain N, Bolm C. ACS Med Chem Lett 11 1928-1934 (2020)
  484. Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells. Yang Y, Yin W, Wu F, Fan J. Onco Targets Ther 10 2993-2999 (2017)
  485. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. Udager AM, DeMarzo AM, Shi Y, Hicks JL, Cao X, Siddiqui J, Jiang H, Chinnaiyan AM, Mehra R. Prostate 76 845-853 (2016)
  486. Domain-selective BET inhibition attenuates transcriptional and behavioral responses to cocaine. Singh MB, Babigian CJ, Sartor GC. Neuropharmacology 210 109040 (2022)
  487. Drug Tolerant Cells: An Emerging Target With Unique Transcriptomic Features. Niveditha D, Sharma H, Sahu A, Majumder S, Chowdhury R, Chowdhury S. Cancer Inform 18 1176935119881633 (2019)
  488. HEXIM1 controls P-TEFb processing and regulates drug sensitivity in triple-negative breast cancer. Shao H, Zhu Q, Lu H, Chang A, Gao C, Zhou Q, Luo K. Mol Biol Cell 31 1867-1878 (2020)
  489. Machine Learning Enables Live Label-Free Phenotypic Screening in Three Dimensions. O'Duibhir E, Paris J, Lawson H, Sepulveda C, Shenton DD, Carragher NO, Kranc KR. Assay Drug Dev Technol 16 51-63 (2018)
  490. Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7. Pan D, Kather M, Willmann L, Schlimpert M, Bauer C, Lagies S, Schmidtkunz K, Eisenhardt SU, Jung M, Günther S, Kammerer B. Int J Mol Sci 17 E1772 (2016)
  491. Scalable syntheses of the BET bromodomain inhibitor JQ1. Syeda SS, Jakkaraj S, Georg GI. Tetrahedron Lett 56 3354-3457 (2015)
  492. Structural and thermodynamic characterization of the binding of isoliquiritigenin to the first bromodomain of BRD4. Yokoyama T, Matsumoto K, Ostermann A, Schrader TE, Nabeshima Y, Mizuguchi M. FEBS J 286 1656-1667 (2019)
  493. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, Zhang T, Gray NS, Gustafson C, Krajewska M, George RE. Front Oncol 11 773186 (2021)
  494. Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research. Yoo M, Park TH, Yoo M, Kim Y, Lee JY, Lee KM, Ryu SE, Lee BI, Jung KY, Park CH. Molecules 26 1686 (2021)
  495. Synthesis and biological evaluation of novel 2,3-dihydrochromeno[3,4-d]imidazol-4(1H)-one derivatives as potent anticancer cell proliferation and migration agents. Han X, Luo J, Wu F, Hou X, Yan G, Zhou M, Zhang M, Pu C, Li R. Eur J Med Chem 114 232-243 (2016)
  496. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Yang Q, Bariani MV, Falahati A, Khosh A, Lastra RR, Siblini H, Boyer TG, Al-Hendy A. Cells 11 2160 (2022)
  497. Unlike Its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. Van Belle S, El Ashkar S, Čermáková K, Matthijssens F, Goossens S, Canella A, Hodges CH, Christ F, De Rijck J, Van Vlierberghe P, Veverka V, Debyser Z. Cells 10 192 (2021)
  498. A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in Cancer. Zhu J, Liu Z, Liang X, Wang L, Wu D, Mao W, Shen D. J Oncol 2022 3982226 (2022)
  499. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Djamai H, Berrou J, Dupont M, Coudé MM, Delord M, Clappier E, Marceau-Renaut A, Kaci A, Raffoux E, Itzykson R, Berthier C, Wu HC, Hleihel R, Bazarbachi A, de Thé H, Baruchel A, Gardin C, Dombret H, Braun T. Biomedicines 9 1704 (2021)
  500. Design, synthesis, and evaluation of novel coumarin-dithiocarbamate derivatives (IDs) as anti-colorectal cancer agents. Zhu H, Ying S, Zhou B, Hu X, Liang X, Li W, Wang D, Jin H, Pan Y. J Enzyme Inhib Med Chem 36 593-604 (2021)
  501. Epigenetic Regulation in Breast Cancer. Nam HJ, Baek SH. Adv Exp Med Biol 1187 103-119 (2021)
  502. Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer. Sun Y, Zhang Z, Zhang K, Liu Y, Shen P, Cai M, Jia C, Wang W, Gu Z, Ma P, Lu H, Guan L, Di W, Zhuang G, Yin X. Am J Cancer Res 11 3021-3038 (2021)
  503. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal of latently HIV-1 infected T cells. Carlin E, Greer B, Lowman K, Duverger A, Wagner F, Moylan D, Dalecki A, Samuel S, Perez M, Sabbaj S, Kutsch O. PLoS Pathog 17 e1008748 (2021)
  504. Functional coordination of BET family proteins underlies altered transcription associated with memory impairment in fragile X syndrome. Kim SK, Liu X, Park J, Um D, Kilaru G, Chiang CM, Kang M, Huber KM, Kang K, Kim TK. Sci Adv 7 eabf7346 (2021)
  505. Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140. Ghiboub M, Koster J, Craggs PD, Li Yim AYF, Shillings A, Hutchinson S, Bingham RP, Gatfield K, Hageman IL, Yao G, O'Keefe HP, Coffin A, Patel A, Sloan LA, Mitchell DJ, Hayhow TG, Lunven L, Watson RJ, Blunt CE, Harrison LA, Bruton G, Kumar U, Hamer N, Spaull JR, Zwijnenburg DA, Welting O, Hakvoort TBM, Te Velde AA, van Limbergen J, Henneman P, Prinjha RK, de Winther MPJ, Harker NR, Tough DF, de Jonge WJ. BMC Biol 20 182 (2022)
  506. Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis. Fu R, Zu SJ, Liu YJ, Li JC, Dang WZ, Liao LP, Liu LP, Chen PY, Huang HM, Wu KH, Zhou B, Pan Q, Luo C, Zhang YY, Li GM. Bioengineered 13 10914-10930 (2022)
  507. Strongylocentrotus nudos Egg Polysaccharide induces autophagy and apoptosis in leukaemia cells by regulating mitochondrial function. Wang C, Li M, Li L, Shen X, Liu Y, Wang S. J Cell Mol Med 25 272-283 (2021)
  508. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells. Kapp N, Stander XX, Stander BA. Anticancer Drugs 29 429-439 (2018)
  509. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. Pal D, Vann KR, Joshi S, Sahar NE, Morales GA, El-Gamal D, Kutateladze TG, Durden DL. iScience 24 102931 (2021)
  510. The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells. Pan H, Lu P, Shen Y, Wang Y, Jiang Z, Yang X, Zhong Y, Yang H, Khan IU, Zhou M, Li B, Zhang Z, Xu J, Lu H, Zhu H. Oncotarget 8 94104-94116 (2017)
  511. Editorial miR-150:targeting MLL leukemia. Jiang X, Chen J. Oncotarget 3 1268-1269 (2012)
  512. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. Smith AL, Eiken AP, Skupa SA, Moore DY, Umeta LT, Smith LM, Lyden ER, D'Angelo CR, Kallam A, Vose JM, Kutateladze TG, El-Gamal D. Int J Mol Sci 23 6712 (2022)
  513. A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R, Colak G, Trojer P, Abramson JS. Cancer Res Commun 2 795-805 (2022)
  514. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. Clin Cancer Res 29 711-722 (2023)
  515. A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy. Zhou Z, Van der Jeught K, Li Y, Sharma S, Yu T, Moulana I, Liu S, Wan J, Territo PR, Opyrchal M, Zhang X, Wan G, Lu X. Adv Sci (Weinh) 10 e2300548 (2023)
  516. Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression. Zhou JX, Agborbesong E, Li LX, Li X. Int J Mol Sci 23 15163 (2022)
  517. Bromodomain-containing protein 4 (BRD4) as an epigenetic regulator of fatty acid metabolism genes and ferroptosis. Yang M, Liu K, Chen P, Zhu H, Wang J, Huang J. Cell Death Dis 13 912 (2022)
  518. Collaboration between PcG proteins and MLL fusions in Leukemogenesis: an emerging paradigm. Zeisig BB, Arteaga MF, Thirant C, So CW. Cancer Cell 20 551-553 (2011)
  519. Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias. Cantilena S, Gasparoli L, Pal D, Heidenreich O, Klusmann JH, Martens JHA, Faille A, Warren AJ, Karsa M, Pandher R, Somers K, Williams O, de Boer J. Clin Transl Med 12 e933 (2022)
  520. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays. Sun Z, Zhang H, Chen Z, Xie Y, Jiang H, Chen L, Ding H, Zhang Y, Jiang H, Zheng M, Luo C. Bioorg Med Chem Lett 27 2003-2009 (2017)
  521. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Morris V, Wang D, Li Z, Marion W, Hughes T, Sousa P, Harada T, Sui SH, Naumenko S, Kalfon J, Sensharma P, Falchetti M, Vinicius da Silva R, Candelli T, Schneider P, Margaritis T, Holstege FCP, Pikman Y, Harris M, Stam RW, Orkin SH, Koehler AN, Shalek AK, North TE, Pimkin M, Daley GQ, Lummertz da Rocha E, Rowe RG. Cell Rep 39 110752 (2022)
  522. Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia. Kerstjens M, Garrido Castro P, Pinhanços SS, Schneider P, Wander P, Pieters R, Stam RW. Biomedicines 9 711 (2021)
  523. Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping. Yang H, Sui P, Guo Y, Chen S, Maloof ME, Ge G, Nihozeko F, Delma CR, Zhu G, Zhang P, Ye Z, Medina EA, Ayad NG, Mesa R, Nimer SD, Chiang CM, Xu M, Chen Y, Yang FC. EMBO Rep 24 e57032 (2023)
  524. Pharmacophore-Model-Based Virtual-Screening Approaches Identified Novel Natural Molecular Candidates for Treating Human Neuroblastoma. Opo FADM, Alkarim S, Alrefaei GI, Molla MHR, Alsubhi NH, Alzahrani F, Ahammad F. Curr Issues Mol Biol 44 4838-4858 (2022)
  525. Introductory Journal Article The epigenetics of cancer: from non-coding RNAs to chromatin and beyond. Castelo-Branco G, Bannister AJ. Brief Funct Genomics 12 161-163 (2013)
  526. Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. He MY, Halford MM, Liu R, Roy JP, Grant ZL, Coultas L, Thio N, Gilan O, Chan YC, Dawson MA, Achen MG, Stacker SA. Commun Biol 4 878 (2021)
  527. What Is the BET on Solid Tumors? Filippakopoulos P. J Clin Oncol 36 3040-3042 (2018)
  528. N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells. Nord JA, Wynia-Smith SL, Gehant AL, Jones Lipinski RA, Naatz A, Rioja I, Prinjha RK, Corbett JA, Smith BC. Front Endocrinol (Lausanne) 13 923925 (2022)
  529. BET Proteins Regulate Expression of Osr1 in Early Kidney Development. Schreiber J, Liaukouskaya N, Fuhrmann L, Hauser AT, Jung M, Huber TB, Wanner N. Biomedicines 9 1878 (2021)
  530. BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma. Funck-Brentano E, Vizlin-Hodzic D, Nilsson JA, Nilsson LM. Epigenetics 16 54-63 (2021)
  531. BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis. Wang X, Sang M, Gong S, Chen Z, Zhao X, Wang G, Li Z, Huang Y, Chen S, Xie G, Duan E, Sun F. Genes Dis 9 1062-1073 (2022)
  532. BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma. Zhang M, Wang G, Ma Z, Xiong G, Wang W, Huang Z, Wan Y, Xu X, Hoyle RG, Yi C, Hou J, Liu X, Chen D, Li J, Wang C. Mol Ther 30 3394-3413 (2022)
  533. Comment BETting on a new prostate cancer treatment. Asangani IA, Chinnaiyan AM. Cell Cycle 13 2015-2016 (2014)
  534. BRD4 interacts with PML/RARα in acute promyelocytic leukemia. Luo Q, Deng W, Wang H, Fan H, Zhang J. Front Med 12 726-734 (2018)
  535. Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis. Banham GD, Lee CYC, Ferdinand JR, Matthews RJ, Jing C, Smithers N, Prinjha RK, Clatworthy MR. Front Immunol 13 885101 (2022)
  536. Bromodomain and Extraterminal Inhibition by JQ1 Produces Divergent Transcriptional Regulation of Suppressors of Cytokine Signaling Genes in Adipocytes. Mota de Sá P, Richard AJ, Stephens JM. Endocrinology 161 bqz034 (2020)
  537. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Quintela M, James DW, Pociute A, Powell L, Edwards K, Coombes Z, Garcia J, Garton N, Das N, Lutchman-Singh K, Margarit L, Beynon AL, Rioja I, Prinjha RK, Harker NR, Gonzalez D, Conlan RS, Francis LW. Clin Epigenetics 15 63 (2023)
  538. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Imayoshi N, Yoshioka M, Tanaka K, Yang SM, Akahane K, Toda Y, Hosogi S, Inukai T, Okada S, Maloney DJ, Nakahata T, Takita J, Kato I, Ashihara E. Biochem Biophys Res Commun 590 49-54 (2022)
  539. CRISPR-ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia. Gilan O, Talarmain L, Bell CC, Neville D, Knezevic K, Ferguson DT, Boudes M, Chan YC, Davidovich C, Lam EYN, Dawson MA. Nat Struct Mol Biol 30 1592-1606 (2023)
  540. Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia. Zhang MF, Luo XY, Zhang C, Wang C, Wu XS, Xiang QP, Xu Y, Zhang Y. Acta Pharmacol Sin 43 2735-2748 (2022)
  541. Efficient Differentiation of Mouse Induced Pluripotent Stem Cells into Alveolar Epithelium Type II with a BRD4 Inhibitor. Momozane T, Fukui E, Funaki S, Fujii M, Kinehara Y, Ito E, Miyagawa S, Ohno Y, Sawa Y, Okumura M, Shintani Y. Stem Cells Int 2019 1271682 (2019)
  542. Editorial Elongation vs stalling: place your BET. Donato E, Croci O, Campaner S. Oncotarget 8 110737-110738 (2017)
  543. Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach. Sender S, Sultan AW, Palmer D, Koczan D, Sekora A, Beck J, Schuetz E, Taher L, Brenig B, Fuellen G, Junghanss C, Murua Escobar H. Cancers (Basel) 14 4691 (2022)
  544. Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to COL1A1-PDGFB fusion gene. Hirose T, Ikegami M, Kojima S, Yoshida A, Endo M, Shimada E, Kanahori M, Oyama R, Matsumoto Y, Nakashima Y, Kawai A, Mano H, Kohsaka S. Cancer Sci 114 4089-4100 (2023)
  545. Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening. Gao N, Ren J, Hou L, Zhou Y, Xin L, Wang J, Yu H, Xie Y, Wang H. Int J Mol Med 38 39-44 (2016)
  546. Maintenance of cell fates through acetylated histone and the histone variant H2A.z in C. elegans. Shibata Y, Nishiwaki K. Worm 3 e29048 (2014)
  547. Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. Chabert C, Khochbin S, Rousseaux S, Furze R, Smithers N, Prinjha R, Schlattner U, Pison C, Dubouchaud H. Sci Rep 7 12133 (2017)
  548. NMR Molecular Replacement Provides New Insights into Binding Modes to Bromodomains of BRD4 and TRIM24. Torres F, Walser R, Kaderli J, Rossi E, Bobby R, Packer MJ, Sarda S, Walker G, Hitchin JR, Milbradt AG, Orts J. J Med Chem 65 5565-5574 (2022)
  549. Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Tregnago C, Benetton M, Da Ros A, Borella G, Longo G, Polato K, Francescato S, Biffi A, Pigazzi M. Front Pharmacol 12 820191 (2021)
  550. Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-a]pyrazin-8(7H)-one as Novel BRD4 Inhibitors. Yang Y, Chen P, Zhao L, Zhang F, Zhang H, Zhou J. ACS Med Chem Lett 10 1680-1685 (2019)
  551. Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors. Yan G, Hou M, Luo J, Pu C, Hou X, Lan S, Li R. Chem Biol Drug Des 91 478-490 (2018)
  552. Streamlined DNA-encoded small molecule library screening and validation for the discovery of novel chemotypes targeting BET proteins. Jeong S, Kim HR, Shin JH, Son MH, Lee IH, Roe JS. Mol Ther Nucleic Acids 32 637-649 (2023)
  553. Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities. Liu L, Zhu Y, Liu Z, Ye T, Zuo W, Peng C, Xiao K, Wang N, Yu L. Mol Divers 21 125-136 (2017)
  554. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity. Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Neoplasia 41 100902 (2023)
  555. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Blood Cancer J 13 53 (2023)
  556. The Trithorax group protein ASH1 requires a combination of BAH domain and AT hooks, but not the SET domain, for mitotic chromatin binding and survival. Steffen PA, Altmutter C, Dworschak E, Junttila S, Gyenesei A, Zhu X, Kockmann T, Ringrose L. Chromosoma 130 215-234 (2021)
  557. The converging roles of BRD4 and gene transcription in pluripotency and oncogenesis. Wu T, Donohoe ME. RNA Dis 2 e894 (2015)
  558. Editorial 2011: Signaling breakthroughs of the year. Adler EM. Sci Signal 5 eg1 (2012)
  559. A Dual Role for FADD in Human Precursor T-Cell Neoplasms. Marín-Rubio JL, Vela-Martín L, Gudgeon J, Pérez-Gómez E, Sidgwick FR, Trost M, Cunningham DL, Santos J, Fernández-Piqueras J, Villa-Morales M. Int J Mol Sci 23 15157 (2022)
  560. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4. Yang L, Jing Y, Xia X, Yin X. J Oncol 2023 9904143 (2023)
  561. Acid-Promoted Cascade Reaction of N-(4-Chloroquinolin-3-yl)carbamates with Amines: One-Pot Assembly of Imidazo[4,5-c]quinolin-2-one. Lu X, Kim M, Orr MJ, Li H, Huang W. European J Org Chem 2018 1572-1580 (2018)
  562. BETting on next-generation bromodomain inhibitors. Collins MK, Chau CH, Price DK, Figg WD. Am J Clin Exp Urol 8 129-132 (2020)
  563. Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors. Flynn NR, Ward MD, Schleiff MA, Laurin CMC, Farmer R, Conway SJ, Boysen G, Swamidass SJ, Miller GP. Metabolites 11 390 (2021)
  564. Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. Pérez-Salvia M, Simó-Riudalbas L, Llinàs-Arias P, Roa L, Setien F, Soler M, Castro de Moura M, Bradner JE, Gonzalez-Suarez E, Moutinho C, Esteller M. Oncotarget (2017)
  565. Chemical Inhibition of Bromodomain Proteins in Insect-Stage African Trypanosomes Perturbs Silencing of the Variant Surface Glycoprotein Repertoire and Results in Widespread Changes in the Transcriptome. Ashby EC, Havens JL, Rollosson LM, Hardin J, Schulz D. Microbiol Spectr 11 e0014723 (2023)
  566. Concerted bioinformatic analysis of the genome-scale blood transcription factor compendium reveals new control mechanisms. Joshi A, Gottgens B. Mol Biosyst 10 2935-2941 (2014)
  567. Congress Conference scene: 2nd cancer epigenetics conference. Smith CL. Epigenomics 5 123-130 (2013)
  568. Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study. Kim JH, Pandit N, Yoo M, Park TH, Choi JU, Park CH, Jung KY, Lee BI. Sci Rep 13 10805 (2023)
  569. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors. Li X, Zhang J, Zhao L, Yang Y, Zhang H, Zhou J. ChemMedChem 13 1363-1368 (2018)
  570. Drug-induced loss of imprinting revealed using bioluminescent reporters of Cdkn1c. Dimond A, Van de Pette M, Taylor-Bateman V, Brown K, Sardini A, Whilding C, Feytout A, Prinjha RK, Merkenschlager M, Fisher AG. Sci Rep 13 5626 (2023)
  571. Dynamic changes of enhancer and super enhancer landscape in degenerated nucleus pulposus cells. Li G, Kang Y, Feng X, Wang G, Yuan Y, Li Z, Du L, Xu B. Life Sci Alliance 6 e202201854 (2023)
  572. Enhancer in cancer pathogenesis and treatment. Sun Z, Fan J, Dang Y, Zhao Y. Genet Mol Biol 46 e20220313 (2023)
  573. Epigenetic Markers Associated with Schistosomiasis. Gomes Assenço RA, Alves Mota E, De Oliveira VF, De Castro Borges W, Guerra-Sá R. Helminthologia 58 28-40 (2021)
  574. Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines. Boehm D, Ott M. Bio Protoc 7 e2314 (2017)
  575. Comment Hematopoietic stem cells made BETter by inhibition. Marando L, Huntly BJP. Haematologica 103 919-921 (2018)
  576. Inhibition of the BET family of epigenetic reader proteins: A novel principle for modulating gene expression in IgE-activated mast cells. Garcia-Faroldi G, Rönnberg E, Grujic M, Pejler G. Immun Inflamm Dis 5 141-150 (2017)
  577. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Färber B, Lapshyna O, Künstner A, Kohl M, Sauer T, Bichmann K, Heckelmann B, Watzelt J, Honselmann K, Bolm L, Ten Winkel M, Busch H, Ungefroren H, Keck T, Gemoll T, Wellner UF, Braun R. Front Oncol 13 1230382 (2023)
  578. RUNX1 colludes with NOTCH1 to reprogram chromatin in T cell acute lymphoblastic leukemia. Islam R, Jenkins CE, Cao Q, Wong J, Bilenky M, Carles A, Moksa M, Weng AP, Hirst M. iScience 26 106795 (2023)
  579. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML. Di Mambro A, Arroyo-Berdugo Y, Fioretti T, Randles M, Cozzuto L, Rajeeve V, Cevenini A, Austin MJ, Esposito G, Ponomarenko J, Lucas CM, Cutillas P, Gribben J, Williams O, Calle Y, Patel B, Esposito MT. Oncogene (2023)
  580. Selective BD2 Inhibitor Exerts Anti-Fibrotic Effects via BRD4/FoxM1/Plk1 Axis in Orbital Fibroblasts From Patients With Thyroid Eye Disease. Xie Y, Pan Y, Chen Q, Chen Y, Chen G, Wang M, Zeng P, Li Z, Li Z, Wang S, Yang H, Liang D. Invest Ophthalmol Vis Sci 64 9 (2023)
  581. Spinal-Specific Super Enhancer in Neuropathic Pain. Tao Y, Wang QH, Li XT, Liu Y, Sun RH, Xu HJ, Zhang M, Li SY, Yang L, Wang HJ, Hao LY, Cao JL, Pan Z. J Neurosci 43 8547-8561 (2023)
  582. Synthesis and characterization of I-BET151 derivatives for use in identifying protein targets in the African trypanosome. Poli ANR, Blyn RC, Buenconsejo GY, Hodanu M, Tang E, Danh C, Cassel J, Debler EW, Schulz D, Salvino JM. Curr Res Chem Biol 3 100047 (2023)
  583. Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer. Shen P, Ye K, Xiang H, Zhang Z, He Q, Zhang X, Cai MC, Chen J, Sun Y, Lin L, Qi C, Zhang M, Cheung LWT, Shi T, Yin X, Li Y, Di W, Zang R, Tan L, Zhuang G. Sci Adv 9 eadj0123 (2023)
  584. Comment Therapeutics: Click and discover. Vassiliou GS, Balasubramanian S. Nature 548 162-164 (2017)
  585. Transcriptional variability accelerates preleukemia by cell diversification and perturbation of protein synthesis. Gupta S, Dovey OM, Domingues AF, Cyran OW, Cash CM, Giotopoulos G, Rak J, Cooper J, Gozdecka M, Dijkhuis L, Asby RJ, Al-Jabery N, Hernandez-Hernandez V, Prabakaran S, Huntly BJ, Vassiliou GS, Pina C. Sci Adv 8 eabn4886 (2022)
  586. [Histone modification aberrations in acute myeloid leukemia and the target therapy development in clinical settings]. Guo HD, Chu YJ, Yuan WP. Zhonghua Xue Ye Xue Za Zhi 39 171-176 (2018)
  587. [In vitro study of BRD4 inhibitor GSK525762A against primary adult common B-cell acute lymphoblastic leukemia cells in vitro]. Ma S, Chen C, Zhu J, Li Y, Wang X, Song X, Cao J, Xu K. Zhonghua Xue Ye Xue Za Zhi 36 563-569 (2015)


Quick links